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ABSTRACT 
Vitamin D is vital for normal growth and development. Vitamin D is produced 
endogenously in the skin after sunlight exposure or obtained from dietary 
sources. In Finland, solar radiation is inadequate for cutaneous vitamin D 
synthesis in winter, leading to a high risk for vitamin D insufficiency, defined 
by circulating 25-hydroxyvitamin D concentration [25(OH)D] below 50 
nmol/l. Poor maternal 25(OH)D has been associated with adverse pregnancy 
and neonatal outcomes, such as pre-eclampsia, gestational diabetes mellitus 
(GDM), and low birth weight. Only a few studies have explored the 
relationship between vitamin D and infant postnatal growth, and these studies 
show inconsistent results. Further, data on current maternal vitamin D status 
and infant vitamin D intake in Finland are lacking. 
The objectives of this thesis were to 1) define maternal and newborn 
25(OH)D concentrations and characterize maternal determinants of vitamin 
D status during pregnancy; 2) examine whether vitamin D status differs 
between mothers with and without GDM; 3) describe vitamin D intake from 
food and identify food sources of vitamin D in 1-year-old infants, and finally, 
4) investigate whether maternal or infant vitamin D status associate with pre- 
and postnatal infant growth. 
This thesis is part of the Vitamin D Intervention in Infants (VIDI) study. At 
Helsinki Maternity Hospital, 987 families were recruited to the study from 
January 2013 to June 2014. Infants were randomized to daily supplemental 
vitamin D dosages of 10 μg or 30 μg from 2 weeks until 2 years of age. Mothers 
were of Northern European ethnicity without regular medication. Infants were 
born at term with birth weights appropriate for gestational age. Maternal 
serum samples were collected at prenatal clinics between 2012 and 2013 in 
early pregnancy. At birth, umbilical cord blood (UCB) was obtained. 
Circulating 25(OH)D was analyzed with IDS-iSYS from pregnancy, UCB and 
infant serum samples at 1 year of age. Maternal dietary patterns were derived 
from a 22-item food frequency questionnaire and infant vitamin D intake was 
assessed with a 3-day food record. GDM diagnosis and data on infant birth size 
were obtained from medical records. Infant growth was measured at study 
visits at the ages of 6 months and 1 year.  
Overall, the pregnant women and their newborns were vitamin D sufficient 
as the concentration of 25(OH)D in 96% of all subjects was ≥50 nmol/l. Of 
pregnant women, 95% used vitamin D supplements with a mean daily intake 
of 16 μg. Maternal positive predictors of 25(OH)D during pregnancy, based on 
25(OH)D from early pregnancy to UCB, were supplemental vitamin D intake, 
a dietary pattern characterized by regular use of vitamin D–fortified foods and 
prepregnancy physical activity. In contrast, factors associating with declining 
25(OH)D during pregnancy were smoking and multiparity.  
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GDM was observed in 11% of the pregnant women. Maternal 25(OH)D 
concentrations did not differ between GDM and non-GDM women. 
Furthermore, 25(OH)D had no relation to oral glucose tolerance test results. 
Mean daily intake of vitamin D from food was 7.5 μg in non-breastfed and 3.8 
μg in breastfed 1-year-old infants. The main food sources of vitamin D were 
infant formula, dairy milk, porridge, and fish foods. 
Higher maternal and infant 25(OH)D were associated with slower infant 
growth. At 6 months of age, infants to mothers with high pregnancy 25(OH)D 
(>125 nmol/l) were the shortest (in length), lightest (in weight), and thinnest 
(in length-adjusted weight). Higher UCB 25(OH)D had an inverse association 
with head circumference at birth and infant length at 6 months. In infants, 
higher UCB 25(OH)D associated with slower linear growth from birth to 6 
months, but an accelerated growth from 6 months to 1 year of age. Infants with 
25(OH)D >125 nmol/l were the lightest and thinnest at 1 year of age, whereas 
mothers with UCB 25(OH)D <50 nmol/l had the thinnest infants at 6 months. 
In conclusion, vitamin D status was sufficient among pregnant women in 
Finland. Likewise, infants who participated in a vitamin D supplementation 
trial had sufficient vitamin D status at 1 year of age. High maternal and infant 
25(OH)D associated with slower infant growth. These results may indicate a 
possible inverse U-shaped relationship between vitamin D status and growth. 
The clinical relevance of this finding remains unknown. Until more data 
emerge, there is no need to aim for higher maternal or infant 25(OH)D 
concentrations beyond vitamin D sufficiency with excessive supplementation 
as this may have disadvantageous effects on infant growth.  
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TIIVISTELMÄ 
D-vitamiini on välttämätöntä normaalille kasvulle ja kehitykselle. D-
vitamiinia muodostuu iholla auringonvalon vaikutuksesta ja sitä saadaan 
myös ruuasta tai ravintovalmisteista. Suomessa auringonvalo on riittämätöntä 
talviaikaan ihon D-vitamiinisynteesille lisäten D-vitamiinin puutoksen riskiä. 
Elimistön D-vitamiinitaso määritetään veren 25-hydroksi-D-
vitamiinipitoisuutena [25(OH)D]. D-vitamiinitaso on riittämätön 25(OH)D-
pitoisuuden ollessa alle 5o nmol/l. Raskausajan alhainen 25(OH)D-pitoisuus 
on yhdistetty raskauskomplikaatioihin, kuten raskausmyrkytykseen ja 
raskausdiabetekseen, sekä vastasyntyneen pienipainoisuuteen. Vain harvat 
tutkimukset ovat selvittäneet D-vitamiinin ja syntymän jälkeisen kasvun 
välisiä yhteyksiä, ja nämäkin tutkimustulokset ovat olleet keskenään 
ristiriitaisia. Suomalaisten raskaana olevien naisten D-vitamiinitasosta ja 
pikkulasten nykyisestä D-vitamiinin saannista ei ole ajantasaista tietoa.  
Tämän väitöskirjan tavoitteet olivat 1) selvittää raskaana olevien naisten ja 
vastasyntyneiden D-vitamiinitaso sekä kuvata tekijät, jotka vaikuttavat 
25(OH)D-pitoisuuteen raskausaikana; 2) tutkia eroaako raskausajan 
25(OH)D-pitoisuus raskausdiabetesta sairastavien ja ei-sairastavien välillä; 3) 
kuvata 1-vuotiaiden lasten D-vitamiinin saanti ruuasta ja ravinnon 
tärkeimmät D-vitamiinin lähteet ja lopuksi 4) tutkia onko raskausajan tai 
varhaislapsuuden 25(OH)D-pitoisuus yhteydessä sikiöaikaiseen ja 
varhaislapsuuden kasvuun. 
Väitöskirja on osa Lasten D-vitamiini -tutkimusta (VIDI). VIDI-
tutkimukseen on rekrytoitu Helsingin Kätilöopiston sairaalassa vuosien 
2013–14 aikana 987 lasta perheineen lapsen syntymän jälkeen. Lapset 
satunnaistettiin saamaan päivittäin D-vitamiinivalmistetta joko 10 μg tai 30 
μg alkaen kahden viikon iästä kahden vuoden ikään saakka. Äidit olivat 
pohjoiseurooppalaista syntyperää ilman säännöllistä lääkitystä. Lapset olivat 
syntyneet täysiaikaisina ja syntymäpaino oli normaali raskauden kestoon 
nähden. Äitien alkuraskauden verinäytteet olivat kerätty normaalin 
neuvolaseurannan yhteydessä vuosina 2012-13 ja säilytetty 
Äitiysneuvolaseerumipankissa. Syntymän yhteydessä otettiin napaverinäyte. 
Veren 25(OH)D-pitoisuudet mitattiin raskausajan verinäytteestä, napaverestä 
sekä lapsen verinäytteestä hänen ollessaan 1 vuoden ikäinen. Raskausajan 
ruuankäyttötieto kerättiin 22-kohtaisella frekvenssikyselylomakkeella, ja 
lapsen D-vitamiinin saanti laskettiin kolmen päivän ruokapäiväkirjan avulla 
lapsen ollessa 1 vuoden ikäinen. Tiedot raskausdiabeteksesta ja 
syntymäkoosta kerättiin terveydenhuollon rekistereistä. Lapsen koko 
mitattiin tutkimuskäynneillä 6 kuukauden ja 1 vuoden iässä. 
Raskaana olevien naisten ja vastasyntyneiden D-vitamiinitilanne oli 
riittävä, sillä suurimmalla osalla veren 25(OH)D-pitoisuus oli vähintään 50 
nmol/l. Raskaana olevista naisista 95% käytti D-vitamiinivalmistetta ja 
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keskimääräinen D-vitamiinin saanti ravintovalmisteista oli 16 μg. 
Raskausajan 25(OH)D-pitoisuutta lisäsivät suurempi D-vitamiinin saanti 
valmisteista, ruokavaliotyyli, johon liittyi säännöllinen D-vitaminoitujen 
ruokien käyttö sekä liikunnallinen aktiivisuus ennen raskautta. Tupakointi ja 
monisynnyttäneisyys vähensivät 25(OH)D-pitoisuutta raskauden aikana. 
Raskausdiabetes oli todettu 11% raskaana olevista naisista. Raskausajan 
25(OH)D-pitoisuus ei eronnut raskausdiabetesta sairastavien ja ei-
sairastavien välillä. Lisäksi 25(OH)D-pitoisuus ei ollut yhteydessä 
gluukosirasituskokeen tuloksiin. Pikkulasten keskimääräinen päivittäinen D-
vitamiinin saanti ruuasta oli 7.5 μg ei-imetetyillä ja 3.8 μg imetetyillä 1 vuoden 
iässä. Pääasialliset D-vitamiinin saantilähteet olivat äidinmaidonkorvike, 
maito, puuro ja kalaruuat 1-vuotiailla lapsilla. 
Korkeampi raskausajan ja pikkulapsen 25(OH)D-pitoisuus oli yhteydessä 
lapsen hitaampaan kasvuun. Kuuden kuukauden iässä lyhyimmät, kevyimmät 
ja laihimmat lapset olivat ne, joiden äideillä oli alkuraskauden 25(OH)D-
pitoisuus yli 125 nmol/l. Korkeampi napaveren 25(OH)D-pitoisuus oli 
yhteydessä vastasyntyneen pienempään päänympärykseen sekä hitaampaan 
pituuskasvuun 6 kuukauden iässä. Korkeampi napaveren 25(OH)D-pitoisuus 
oli yhteydessä hitaampaan kasvuvauhtiin syntymästä 6 kuukauden ikään 
saakka, mutta kiihtyneeseen kasvuvauhtiin 6 kuukauden jälkeen 1 vuoden 
ikään saakka. Lapset, joilla oli korkea 25(OH)D-pitoisuus 1 vuoden iässä 
(25(OH)D >125 nmol/l) olivat myös kevyimmät ja laihimmat 1 vuoden iässä. 
Toisaalta, lapset, joilla napaveren 25(OH)D oli alle 50 nmol/l, olivat 
laihimmat 6 kuukauden iässä. 
Yhteenvetona voidaan todeta, että raskaana olevien naisten D-
vitamiinitaso oli riittävä. Samoin myös D-vitamiini-interventiotutkimukseen 
osallistuneiden pikkulasten D-vitamiinitaso oli riittävä. Korkea raskausajan ja 
varhaislapsuuden 25(OH)D-pitoisuus oli yhteydessä lapsen hitaampaan 
kasvuun. Nämä tulokset voivat viitata käänteiseen U-käyrän muotoiseen 
yhteyteen D-vitamiinin ja kasvun välillä. Löydöksen kliinistä merkitystä ei 
tiedetä. Tämän hetkisen tiedon valossa ei ole syytä tavoitella riittävän 
25(OH)D-pitoisuuden ylittäviä pitoisuuksia syömällä suurempia D-
vitamiiniannoksia raskauden tai varhaislapsuuden aikana, koska sillä voi olla 
epäedullisia vaikutuksia lapsen kasvuun.  
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1 INTRODUCTION 
Vitamin D is vital for child development and growth and for maintaining 
mineral homeostasis required for normal body functions. Vitamin D is 
produced endogenously in the skin induced by solar ultraviolet light B (UVB). 
Other sources of vitamin D are food—mainly fish and fortified foods—and 
supplements. Vitamin D status is determined by blood 25-hydroxyvitamin D 
concentration [25(OH)D], but the definition for sufficient vitamin D status is 
under debate [1]. Severe vitamin D deficiency increases the risk of the 
disabling bone disease rickets in children and osteomalacia in adults. Indeed, 
traditionally, the main function of vitamin D has been regarded to be the 
maintenance of bone health and calcium-phosphate homeostasis. Recently, it 
has been observed that vitamin D influences processes beyond bone and 
mineral metabolism, and a vast amount of research has associated vitamin D 
deficiency with several extraskeletal diseases and conditions [2]. In addition, 
vitamin D status has also been recognized as a general health status indicator, 
associating, for example, with obesity, smoking, and physical activity [3, 4]. 
Therefore, it is unclear whether the relationships between vitamin D and 
health outcomes are causal [5]. 
Early-life nutrition has long-lasting consequences on offspring health. 
Maternal and infant undernutrition causes growth retardation and low birth 
weight. According to Barker’s theory (or the Developmental Origins of Health 
and Disease hypothesis), this early-life growth restriction further leads to 
metabolic programming and an increased risk of several chronic diseases later 
in life [6-8]. Growth patterns during infancy may have long-lasting 
consequences for health later in life [9]. Associations between pre- and 
postnatal growth patterns and disease risk have also been found within the 
normal birth weight range, and studies suggest that this relationship is U- or 
J-shaped [10-13]. Vitamin D may be one contributing factor in the 
developmental origins of disease [14-16]. Furthermore, low maternal vitamin 
D status has been associated with adverse pregnancy outcomes, such as 
gestational diabetes mellitus (GDM), low birth weight, and small-for-
gestational-age (SGA) [17], but the evidence is inconclusive [18]. GDM, 
moreover, increases the risk for type 2 diabetes, metabolic syndrome, obesity, 
and cardiovascular diseases later in life, both in the mother and in the child 
[19, 20]. 
Active discussion about optimal vitamin D status is ongoing [21-23]. Due 
to revised national vitamin D food fortification and supplementation policies, 
vitamin D intake has increased and vitamin D deficiency decreased in Finnish 
adults [24-26]. However, updated data on vitamin D intake and the status of 
pregnant women and infants are lacking. The objective of this thesis was to 
study the current vitamin D status among Finnish pregnant women and 
whether it associates with GDM, infant birth size, and postnatal growth in 
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term infants with normal birth weight, and whether infant vitamin D status 
relates to infant growth at 1 year of age. This thesis is part of the Vitamin D 
Intervention in Infants (VIDI) study. 
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2 REVIEW OF THE LITERATURE 
2.1 VITAMIN D 
The concept of a vitamin was first introduced by Casimir Funk in the early 
1900s [27, 28]. A vitamin is defined as an essential dietary compound for 
normal growth, development, and health and cannot be synthesized by the 
organism itself. However, fat-soluble vitamin D can be regarded as a steroid 
hormone, which can be synthesized in the skin in the presence of sufficient 
sunlight. If sufficient ultraviolet light B (UVB) radiation is lacking, the only 
sources of vitamin D are food and supplements. 
The history of vitamin D begins with the identification of a severe bone 
disease, rickets, which is characterized by leg deformity, osteopenia, swelling 
of the wrists and ankles, and growth retardation in children. The term was first 
mentioned as a cause of death in 1634 in London (Annual Bill of Mortality of 
the City of London) [29]. During the phase of industrialization and 
urbanization, in many European and American cities with limited sunlight 
exposure, rickets was highly common among children [30]. According to Arvo 
Ylppö in 1925, among Finnish children of pediatric population aged 1 to 2 years 
50-70% suffered from rickets during that time [31]. In the late 1800s, it was 
recognized that rickets was prevented or cured with cod liver oil or sunlight 
exposure. In the early 1900s, Mellanby et al. conducted the first systematic 
intervention with cod liver oil to cure rickets in dogs [32]. After success, the 
researchers suggested that the curative factor in cod liver oil was vitamin A. 
However, McCollum et al. then showed that if vitamin A was destroyed in cod 
liver oil, the oil could still cure rickets [33]. They therefore concluded that 
there must be another factor, which they named vitamin D. Consequently, 
common rickets was recognized as a result of vitamin D deficiency. Soon, 
Steenbock found that, in rats, irradiation of both the rat and its food could 
prevent or cure rickets [34]. 
Evolutionarily, the role of vitamin D in human physiology is not fully 
understood. It has been suggested that originally the purpose of vitamin D was 
to protect organisms from DNA-damaging UVB rays [35]. Furthermore, it has 
been hypothesized that the evolution of skin depigmentation is a result of an 
adaptation to environments with low UVB to ensure adequate vitamin D status 
(The Vitamin D-Folate Hypothesis) [36]. 
2.1.1 VITAMIN D METABOLISM 
Vitamin D refers to several similar molecules, but the main two forms are 
vitamin D3 and vitamin D2. The chemical structure of vitamin D resembles 
classic steroid hormones [37]. Vitamin D3 is produced in the skin from 7-
dehydrocholesterol by solar or artificial UVB. The 7-dehydrocholesterol is first 
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transformed into previtamin D, and through a temperature-dependent 
process, it is further converted to vitamin D3. This endogenous production of 
vitamin D is strictly regulated, and in the presence of prolonged sunlight 
exposure, vitamin D metabolites in the skin are converted to inactive isomers. 
These “inactive” isomers may have other non-vitamin D–related active 
functions in the body [35]. Excessive vitamin D production in the skin is 
prevented by these regulatory mechanisms. In addition to cutaneous 
synthesis, the main natural dietary sources of vitamin D3 are fish and eggs. 
Vitamin D2, originated from ergosterol, is obtained from plant foods such as 
certain types of mushrooms. Other major dietary sources of vitamin D are 
fortified foods. All vitamin D produced in plants or animals is a result of 
photochemical synthesis [38]. 
Though not implicitly shown, the absorption of fat-soluble dietary vitamin 
D is assumed to occur in a similar manner as the absorption of dietary lipids 
or cholesterol [39-41]. Vitamin D is probably more effectively absorbed from 
oil than from a non-oil food matrix, but not all studies agree [39]. Moreover, 
the fatty acid composition possibly has an influence on the efficiency of 
vitamin D absorption [42]. 
Vitamin D is absorbed in the duodenum, jejunum, and ileum, mainly via 
passive diffusion, and possibly also with the help of protein transporters [42]. 
It has been suggested that the mechanism of vitamin D absorption in the small 
intestine may differ according to the supplement vehicles or food matrix in 
which it is incorporated [41] or according to the vitamin D content in the 
ingested food [39]. After absorption, vitamin D is transferred from enterocytes 
in the chylomicrons into the circulation, and it is transported further to the 
liver through chylomicron remnants. 
The biologically active form of vitamin D is metabolized in the liver and 
kidney in reactions catalyzed by vitamin D–activating enzymes. Endogenous 
vitamin D is transported to the liver while bound to the vitamin D binding 
protein (DBP). In the liver, both dietary and endogenous vitamin D are 
hydroxylated into 25-hydroxyvitamin D [25(OH)D], which reflects the vitamin 
D intake from cutaneous synthesis and dietary sources and is the best indicator 
of vitamin D status [43]. Although other metabolites of vitamin D may also 
contribute to vitamin D status [44]. There is a non-linear dose-response 
relationship between vitamin D intake and circulating 25(OH)D 
concentration, with the response decreasing at higher vitamin D intake [45]. 
Vitamins D2 and D3 are equally bioavailable in rising circulating 25(OH)D 
concentration, but vitamin D3 possibly sustains the 25(OH)D level for a longer 
period than vitamin D2 [39]. Further, specific biological mechanisms may have 
some differences between vitamin D2 and D3 metabolites, but for example, 
both prevent and cure vitamin D deficiency rickets with similar efficacy [39]. 
A second hydroxylation occurs in the kidney, resulting in 1,25-
dihydroxyvitamin D [1,25(OH)2D], the most active form of vitamin D.  These 
conversion efficacies differ between the phases of vitamin D metabolism, and 
are dependent on other factors such as baseline vitamin D status [46-48], and 
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dosage [39, 49]. DBP is also a transport protein for 25(OH)D and 1,25(OH)2D. 
The latter can also be produced locally in target organs, for example, in the 
placenta, brain, intestine, mammary gland, prostate [37], and adipocytes [50].  
Vitamin D is stored mainly in fat deposits in the body and, to some extent, 
in the muscle. Obesity decreases circulating 25(OH)D levels, possibly due to 
volumetric dilution [51] and increased vitamin D storage in adipose tissue 
[52]. In some studies, but not in all, weight loss has been associated with 
increased vitamin D status [53]. Besides storage, vitamin D in fat tissue can 
have also active functions, for example, anti-inflammatory effects. Vitamin D 
may be mobilized slowly from fat tissue into circulation when needed [53, 54], 
but the mechanisms are unclear. 
Vitamin D is not easily excreted due to its lipophilic nature. To excrete 
vitamin D metabolites, they must first be transformed into more water-soluble 
compounds, e.g., calcitroic acid, by additional hydroxylations. Vitamin D is 
mainly excreted in the bile [55]. Enterohepatic circulation of vitamin D does 
occur, but its importance for vitamin D (re)activation and excretion is still 
unknown [56]. 
2.1.2 VITAMIN D FUNCTIONS AND REGULATION 
Vitamin D is best known for maintaining bone and calcium-phosphate 
homeostasis. Through vitamin D receptor (VDR), 1,25(OH)2D regulates gene 
transcription in several organs and also acts directly upon target tissues, 
without gene transcription, by rapid signal transduction pathways. Major 
target organs for 1,25(OH)2D are the small intestine, kidney, and bone, which 
collectively regulate plasma calcium-phosphate concentrations for normal 
neuromuscular function and bone remodeling. 1,25(OH)2D increases calcium 
and phosphate absorption in small intestine, resorption from bone, and 
reabsorption in the kidney to maintain normal plasma calcium and phosphate 
level. This is also how 1,25(OH)2D provides calcium for bone mineralization 
and formation. Renal production of 1,25(OH)2D is mainly targeted for calcium 
metabolism, but other local and tissue-specific production of 1,25(OH)2D may 
have other functions, depending on the organ [37]. 
Other functions of vitamin D, apart from its major role in bone and calcium 
metabolism, are less well characterized. VDR has been shown to exist in 
various tissues, e.g., brain, lung, muscle, placenta, and many immune cells [37, 
57], indicating that vitamin D has relevant functions outside the bone, 
although its specific actions are not yet fully understood. One established 
extraskeletal function of vitamin D is in the immune system [57, 58]. Already 
in the early 1900s, tuberculosis (TB) was treated with vitamin D–containing 
cod liver oil or sun exposure, and nowadays, few possible mechanisms have 
been reported between vitamin D and TB, although interventions have been 
inconclusive [5, 59]. Many different immunological cell types express vitamin 
D–activating enzymes or only VDR, showing that vitamin D has a specific role 
in their function [5]. Furthermore, vitamin D regulates immunological 
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functions, for example, by increasing production of the antimicrobial peptides 
cathelicidins against pathogens [60, 61]. 
Regulation of 1,25(OH)2D occurs via the parathyroid hormone (PTH), 
whose concentration increases in the presence of low-plasma calcium (or high-
plasma phosphate), leading to increased production of 1,25(OH)2D in the 
kidney. Further regulation takes place through the feedback system, i.e., 
1,25(OH)2D down-regulates its own synthesis. Also, fibroblast growth factor 
23 (FGF23), secreted from bone, has a role in controlling the concentration of 
1,25(OH)2D, including suppressing its production [62]. This is also why 
1,25(OH)2D is not used to determine vitamin D status, as the production is 
highly regulated, and the half-life of 1,25(OH)2D is very short (4–6 hours) [63] 
compared to 25(OH)D (2–3 weeks) [64]. 
2.1.3 EFFECTS OF VITAMIN D DEFICIENCY 
In the absence of endogenous or dietary vitamin D, bone mineralization is 
impaired, and if prolonged, it can lead to nutritional rickets in children and 
osteomalacia in adults. Infants are at increased risk for vitamin D deficiency 
because of limited sunlight exposure and low vitamin D content in breast milk 
[65]. Furthermore, they are at risk of rickets due to intense skeletal growth. 
In severe vitamin D deficiency, serum calcium decreases (hypocalcemia) 
and PTH increases, which leads to decreased renal phosphate reabsorption 
and hypophosphatemia. This eventually results in reduced apoptosis of 
hypertrophic chondrocytes, leading to deformed growth plates and rickets. 
Altogether, in rickets, mineralization of newly-formed bone and growth plates 
is impaired [66-68]. Typically, rickets evolves 6–18 months after birth, when 
calcium homeostasis becomes more dependent on vitamin D intake [69]. 
Clinical manifestations of rickets are long bone deformities, enlargement of 
wrists and costochondral junctions and stunted linear growth, and infants also 
present with craniotabes and delayed fontanelle closure. In radiological 
examination, widened growth plates and impaired bone mineralization can be 
determined [66]. Severe vitamin D deficiency causes hypocalcemia and may 
lead to severe complications such as seizures, cardiomyopathy, and even death 
[70]. In severe vitamin D deficiency, hypocalcemia usually occurs first [69], 
but it is then regulated to normal by increased PTH at the expense of bone. 
However, rickets finally evolves and hypocalcemia can re-emerge. Vitamin D–
deficiency rickets can be treated with vitamin D supplementation 
accompanied by adequate calcium intake, and a full recovery is possible [71]. 
Rickets can manifest also because of rare genetic defects involving the 
enzymes required for vitamin D hydroxylation or bone mineralization itself, 
such as hereditary hypophosphatasia [66, 67]. In addition, nutritional rickets 
can result from calcium or phosphorus deprivation or, in many cases, 
simultaneous deprivation of vitamin D and calcium [67, 71, 72]. However, the 
most common cause of rickets is vitamin D deficiency [67], although low 
intake of calcium may be the predominant cause in some areas [73]. In 
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Finland, severe nutritional rickets has disappeared, although some ethnic 
groups can be at increased risk of mild forms of rickets [74]. 
2.1.4 VITAMIN D TOXICITY 
As for all chemical compounds, excessive amounts of vitamin D are toxic; 
intoxication is characterized by hypercalcemic manifestations. It can be 
identified if serum 25(OH)D exceeds 250 nmol/l and the person is suffering 
from hypercalcemia, hypercalciuria, and low serum PTH [71]. Acute vitamin 
D intoxication can follow ingestion of very high vitamin D supplementation, 
such as 4000 μg, [71] and has been reported to occur due to, e.g., 
manufacturing errors in dietary supplements [75]. Symptoms of vitamin D 
intoxication include nausea, poor appetite, vomiting, constipation, thirst, 
muscle weakness, polyuria, and nephrocalcinosis, which can result in renal 
failure and death if not treated. The risk of vitamin D intoxication in children 
is low, but it is a matter of concern [76, 77]. 
2.1.5 VITAMIN D IN PREGNANCY 
Adequate vitamin D status is important in pregnancy for both the mother and 
the fetus, as fetal and postnatal bone formation and growth require adequate 
calcium and mineral supplies. This increased demand for calcium may be 
ensured by the fact that maternal 1,25(OH)2D increases considerably during 
pregnancy [78]. Also, the efficacy of intestinal calcium absorption doubles 
during pregnancy [78]. Fetal vitamin D status correlates with maternal serum 
25(OH)D concentration, which reflects 50–108% of 25(OH)D in umbilical 
cord blood (UCB) [79, 80]. Maternal vitamin D and 1,25(OH)2D do not readily 
cross the placenta, but 25(OH)D does, and it can then be further hydroxylated 
into 1,25(OH)2D [78, 81]. According to Christopher Kovacs, however, it seems 
that the placenta and fetus can maintain calcium-phosphate homeostasis and 
normal bone mineralization quite independently, even in the presence of 
maternal vitamin D deficiency [69, 82]. The fetus obtains calcium and other 
necessary minerals from the mother via placenta despite mildly low maternal 
circulating calcium (Figure 1) [69]. Contrary to Kovacs, some consider that 
severe and chronic maternal vitamin D deficiency can increase the risk of 
hypocalcemia and congenital and infantile rickets in newborns [71, 83]. 
Nevertheless, maternal vitamin D deficiency is not healthy for the pregnant 
woman herself, and poor maternal vitamin D status may have extraskeletal 
effects for the offspring. In normal circumstances, after birth, when the 
maternal supply of calcium and phosphate is discontinued, the newborn’s 
calcium level declines for a short period but is then increased again by the 
newborn’s own production of PTH and 1,25(OH)2D [81].  Breast milk, which 
utilizes calcium from the maternal skeleton, offers adequate calcium intake for 
the infant [84] but not vitamin D (see chapter 2.5.2).  
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Figure 1 Calcium sources of the fetus. The main pathway of calcium is through the placenta into 
fetal bone. Some calcium returns to the maternal circulation, some is reabsorbed by the kidneys, 
and some is excreted by the kidneys into the urine and amniotic fluid, where it may be swallowed 
and absorbed by the intestine. Calcium is also resorbed from bone to maintain the circulating 
calcium concentration. Vitamin D supposedly has no regulatory role in this system. Reprinted and 
modified with permission from Elsevier: Fetal mineral homeostasis in Pediatric Bone, Academic 
Press, Kovacs 2003 [69, 85].   
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2.1.6 ASSESSMENT OF 25(OH)D CONCENTRATION 
It is widely agreed that vitamin D status is determined by serum or plasma 
25(OH)D concentration. However, the methods to assess this metabolite vary 
considerably [86]. Values of 25(OH)D, at least to some extent, depend on the 
applied method, individual laboratory, and within-laboratory variability [87]. 
Thus, the reliability and possibilities for comparisons between studies of 
25(OH)D values are restricted. The most commonly used methods include 
different immunoassays and liquid chromatography methods. Liquid 
chromatography-tandem mass spectrometry (LC-MS/MS) [88] is considered 
the golden standard; however, immunoassays are more commonly used [87]. 
To overcome these methodological challenges, the Vitamin D External Quality 
Assurance Scheme (DEQAS) has been organized to monitor the accuracy and 
reliability of different 25(OH)D assays and laboratories (www.deqas.org). This 
is achieved by providing standard reference material with assigned 25(OH)D 
content by the National Institute of Standards and Technology (NIST) to 
laboratories analyzing circulating 25(OH)D. In addition, the Vitamin D 
Standardization Program (VDSP) aims to standardize 25(OH)D 
measurements globally to make them comparable and accurate among 
laboratories and studies [89]. Standardization is especially important when 
reporting prevalence figures of vitamin D deficiency. 
2.2 SOURCES OF VITAMIN D 
As described above, vitamin D is endogenously produced in the skin by UVB. 
This is the primary source of vitamin D for the majority of people worldwide. 
Consequently, the amount of sunshine and exposure to sunlight largely 
determines a person’s vitamin D status. Geographical location in terms of 
latitude, weather conditions, season, air pollution, and time of day have a 
profound impact on UVB exposure. In addition, skin pigmentation, clothing, 
outdoor activity, and age affect UVB-mediated vitamin D synthesis in the skin. 
Darker skin pigmentation reduces the production of vitamin D in the skin 
because of its higher content of melanin (“natural sunscreen”), which 
efficiently absorbs solar radiation [35].  
Specker et al. have estimated that sun exposure of 30 min per week in an 
infant wearing only a diaper will ensure adequate 25(OH)D (>27.5 nmol/l) 
based on a small study (n=61) with the majority (n=51) being white-skinned 
infants [90]. In adults, it has been estimated that with skin type 2 (pale) in the 
Boston area (USA), exposing the face, neck, and hands to UVB for 15 min is 
equivalent to 10 μg of dietary vitamin D [91]. To produce vitamin D, UVB has 
to radiate in the wavelengths of 290–315 nm [35]. This sufficient solar 
radiation is not available in the northern latitude during winter, e.g., in 
Finland from October to March. Thus, during this period, the only sources of 
vitamin D are food and supplements. 
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The main dietary sources of vitamin D are fish, egg, mushrooms, vitamin 
D–fortified foods, and supplements. Breast milk is a poor source of vitamin D 
(see section 2.5.2) [65]. Based on the latest national FinDiet survey conducted 
in 2017, which comprises a representative sample of the Finnish adult 
population, the most relevant food sources of vitamin D were fortified fat 
spreads, fortified milk products, and fish [92]. Table 1 shows some nationally 
relevant foods in regards to vitamin D content. Several different fish species 
have relatively high vitamin D content, but less than half (44%) of Finnish 
women consumed fish foods measured by repeated 24-hour recall in the 
FinDiet survey [92]. Animal-based foods also contain 25(OH)D, which 
contributes to vitamin D status; however, the amounts of 25(OH)D in foods 
have rarely been measured [93].  
2.2.1 VITAMIN D FOOD FORTIFICATION 
Food fortification is applied for public health reasons and for consumer 
appeal. Vitamin D fortification strategies were already being applied in the 
1930s to prevent rickets [64]. However, an outbreak of infantile hypercalcemia 
in the UK led to a decrease of vitamin D content in foods [94] and to general 
precaution against vitamin D food fortification [35]. Today, attitudes against 
food fortification and applied practices differ among countries [64]. The basis 
for fortification is either voluntary or by legislation. Currently, countries such 
as the USA, Canada, the UK, Ireland, Sweden, and Finland fortify their foods 
with vitamin D [95, 96]. Staple foods are usually fortified, including fluid milk 
products, fat spreads, cheese, juices, breads, and breakfast cereal [96]. 
In Finland, the national vitamin D fortification policy has been a unique 
approach aiming to decrease vitamin D deficiency in the general population 
[24, 25, 64, 96]. Vitamin D fortification was initiated in 2003 and revised in 
2010 on a voluntary basis, but almost all manufacturers follow the 
recommended policy [95]. Currently, fluid dairy products and dietary fat 
spreads contain vitamin D3 1 μg/100 ml and 20 μg/100 g, respectively. At the 
time of this study, common infant formulas or follow-on infant formulas 
(hereafter referred to as infant formula) most commonly contain 1.3 μg/100 
ml vitamin D3. However, in the near future, vitamin D content will likely 
increase to 1.1–1.8 (maximum of 2.1) μg/100 ml in some products because of 
updated EU legislation [97]. In fortified foods and supplements, vitamin D2 is 
usually derived from irradiated fungi or yeast, and vitamin D3 from fish oil or 
lanolin from lamb wool. Lichen can contain both vitamins D2 and D3 [98]. In 
Finland, foods are fortified with vitamin D3. 
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Table 1 Common vitamin D content in some fresh Finnish foods1 
Food Vitamin D, μg/100g 
Fishes  
   Baltic herring 15.6 
   Perch 15.8 
   Powan, whitefish, lavaret 14.9 
   Roach 10 
   Salmon 8.0 
   Tuna 7.2 
   Zander, pike-perch 6.9 
   Saithe, frozen 1.5 
Egg 2.2 
Cheese, Edam type 0.2 
Pork, minced 0.5 
Chicken breast with skin 0.5 
Mushrooms  
   Funnel chantarelle 15.4 
   Chantarelle 5.8 
   Porcini 2.6 
   Champignon 0.2 
Fortified foods  
   Fat spread 20 
   Fluid milk products 1 
   Infant formula 1.32 
   Oat drink 0.5–1.5 
1 Source: Fineli, the National Food Composition Database, obtained in 
January 2019 
2 This amount was common at the time of this study 
 
2.2.2 ASSESSMENT OF DIETARY VITAMIN D INTAKE 
To evaluate dietary intake of vitamin D, different dietary assessment methods 
are applied. Acknowledging that few foods contain vitamin D and that these 
foods are consumed rarely, it may be challenging to measure dietary intake of 
vitamin D. Day-to-day variation in diet should be taken into consideration 
when choosing a suitable dietary assessment method and interpreting results 
[99]. 
A food record, often considered the golden method in dietary assessment, 
is a valid method to evaluate a person’s absolute vitamin D intake from food. 
In this prospective method, the study participant records all consumed foods, 
drinks, and supplements and the amounts eaten over a specific period of time, 
generally from three to seven days. The amounts are often estimated with 
household measures, or foods are weighed on a scale. The food record requires 
good instructions for the participant, preferably face-to-face discussion and in 
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written. In addition, food records should be checked retrospectively to avoid 
missing data or false interpretations. A longer study period usually produces 
more valid results. However, long recording period is laborious for the 
participant, which can also compromise accuracy and is often not possible due 
to a lack of research resources. In a group level and with young children, 
shorter study periods also deliver reliable results.  
Other commonly used methods include single and repeated 24-hour recall 
and the food frequency questionnaire (FFQ). The 24-hour recall involves 
having a trained interviewer that inquires about all the foods and drinks 
consumed by the study participant the previous day. As with a food record, 
this gives an absolute value of vitamin D intake, and if repeated, the reliability 
increases from a single-day 24-hour recall. The FFQ is comprised of a list of 
different foods with ready-made options for frequency of consumption. It is 
completed retrospectively and aims to measure the usual intake of certain 
nutrients/foods over a longer time period than a food record (e.g., a year). The 
FFQ often overestimates nutrient intakes. However, it generally ranks 
individuals correctly according to their actual dietary intake. To compare 
vitamin D intake against the recommendations, a food record may be superior 
to the FFQ as it gives the absolute value of intake. On the other hand, vitamin 
D intake from fish foods might be better derived from FFQ, as fish is 
infrequently consumed. 
To assess vitamin D intake in infants and children, their caregiver must 
record all food and drink. Vitamin D intake from breast milk is not always 
calculated as it is challenging to estimate the consumption of breast milk, and 
vitamin D content in breast milk may vary among individuals [100]. These 
methods require a reliable food composition database and computation 
systems to calculate dietary intake of vitamin D as accurately as possible. 
The true dietary intake of vitamin D or any nutrient is almost impossible to 
achieve due to methodological limitations in dietary assessment. Over- or 
under-reporting may be emphasized in pregnant women who may answer in a 
more socially desirable way. This can also be a relevant issue in an infant’s 
dietary intake. Indeed, it has been reported that parents under-report 
“unhealthy” food intake and over-report “healthy” food intake for their infants 
[101]. However, vitamin D intake and blood 25(OH)D concentration, which 
objectively measure vitamin D intake, consistently correlate with each other. 
To apply 25(OH)D as an indicator of dietary vitamin D intake, it is most 
suitable to do so in populations with minimal sun exposure [102].  
2.3 VITAMIN D RECOMMENDATIONS 
To prevent rickets and maintain sufficient vitamin D status among the 
population, different countries, their health authorities, and health 
organizations have implemented dietary reference values and guidelines for 
vitamin D intake [103]. These actions have nearly eradicated rickets in the vast 
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majority of societies. Some, however, still consider rickets a significant global 
health problem; for example, immigration can increase the incidence of rickets 
[71]. Dietary reference values include recommended intake (and 
recommended dietary allowance), which provides adequate intake of a 
nutrient for 97.5% of the population, and lower and upper intake levels.  
To reach the recommended intakes, in addition to food fortification, 
vitamin D supplementation has been recommended. Many authorities have 
special recommendations for vulnerable groups of people such as pregnant 
and breastfeeding women and children. In Finland, vitamin D 
recommendations have been updated a few times as new evidence has 
emerged. Since the early 1900s, the recommended vitamin D supplementation 
for children has progressively decreased from 100 μg daily to 10 μg [104, 105]. 
Table 2 presents the health authorities’ current recommendations for total 
vitamin D intake and supplemental vitamin D intake for pregnant and 
breastfeeding women and infants. Finnish Nutrition Recommendations [106, 
107] are based on Nordic Nutrition Recommendations (NNR) [108]. Still, 
some additional guidelines vary in Nordic countries, such as for vitamin D 
supplementation. 
In Finland, the current recommended daily total vitamin D intake is 10 μg 
for children and adults, including pregnant and breastfeeding women (Table 
2) but excluding the elderly (≥75 years), for whom 20 μg is recommended 
[106]. The recommendation for vitamin D supplementation for pregnant and 
breastfeeding women is 10 μg/day, as well as for children 1–2 years old. For 
children 2–17 years old, the recommended supplemental vitamin D intake is 
7.5 μg/day. 
Finnish vitamin D supplementation guidelines for infants from 2 weeks to 
1 year of age were revised in fall 2018 due to an updated EU legislation on 
infant formulas [109]. This was done to avoid exceeding the upper intake level 
(UL) of vitamin D in formula-fed infants. Presently, the amount of vitamin D 
supplementation decreases as the consumption of fortified infant formula 
increases until the infant is 1 year old (Table 2, footnote 1). However, during 
this study, a valid recommendation for supplemental vitamin D intake was 10 
μg/day for children 2 weeks of age to 2 years of age, regardless of infant 
formula consumption [110]. 
A lower intake level (LI) of vitamin D is 2.5 μg/day for adults, but no 
threshold for infants has been identified [108]. Currently, ULs are 25, 35, 50, 
and 100 μg/day for infants 0–6 months, 6–12 months, 1–11 years, and youth 
and adults, respectively, as defined by the European Food Safety Authority 
(EFSA) [111]. These values vary to some extent by different authorities.  
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Table 2 A few vitamin D recommendations for pregnant and breastfeeding women and infants by 
different authorities 
 Pregnant and breastfeeding women Infants (until 1 year of age) 
 
Total 
vitamin D 
intake 
Supplemental 
vitamin D 
intake 
Total 
vitamin D 
intake 
Supplemental 
vitamin D 
intake 
Health authority μg/day 
National Nutrition Council/ 
National Institute for Health 
and Welfare (Finland) [106] 
10 10 10 101 
National Food Agency 
(Sweden) [108, 112] 10 - 10 10 
EFSA2 [113] 15 - 10 - 
IOM (presently NAM)3 [114] 15 - 10 - 
WHO/FAO4 [115, 116] 5 - 5 - 
Global consensus on 
prevention of rickets [71] 15 15 10 10 
EFSA, European Food Safety Authority; IOM, Institute of Medicine; NAM, National Academy of Medicine; WHO, 
World Health Organization; FAO, Food and Agriculture Organization of the United Nations 
1 If infant is given 500–800 ml infant formula daily, vitamin D supplementation decreases from 10 to 6 μg/day. If 
the daily amount of infant formula is >800 ml, vitamin D supplementation further decreases to 2 μg/day until 
infant is 1 year of age. Infant formula includes infant follow-on formulas and vitamin D–fortified gruels and 
porridges [109]. 
2 Values are adequate intakes (AI), and only valid in the presence of minimal cutaneous vitamin D synthesis 
3 In the presence of minimal sun exposure 
4 If insufficient vitamin D synthesis 
 
 
2.4 DEFINITIONS FOR VITAMIN D DEFICIENCY AND 
SUFFICIENCY 
A clear consensus of thresholds of vitamin D deficiency and sufficiency is 
lacking [88], not to mention a threshold of optimal vitamin D status. However, 
a widely accepted value for vitamin D sufficiency is 25(OH)D ≥50 nmol/l 
(Table 3). This is applied in adults, children, and pregnant and breastfeeding 
women. In addition, the Institute of Medicine (IOM) (presently the National 
Academy of Medicine [NAM]) has set a threshold for excessive 25(OH)D 
concentration at >125 nmol/l, which may pose possible health risks [114], 
although it is not yet considered toxic. The Endocrine Society favors higher 
25(OH)D values of >75 nmol/l [117] (Table 3).  
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Table 3 Circulating 25-hydroxyvitamin D concentration [25(OH)D] thresholds for vitamin D 
deficiency and sufficiency by different health authorities 
 
Vitamin D deficiency, 
25(OH)D (nmol/l) 
Vitamin D sufficiency, 
25(OH)D (nmol/l) 
EFSA [113] <50 ≥50 
NNR [108] <25 ≥50 
IOM (presently NAM) [114] <30 ≥50 
ECTS [88] <50 ≥50 
Endocrine Society [117] <50 ≥75 
Global consensus on 
prevention of rickets [71] <30 ≥50 
EFSA, European Food Safety Authority; NNR, Nordic Nutrition Recommendations; IOM, Institute of 
Medicine; NAM, National Academy of Medicine; ECTS, European Calcified Tissue Society 
 
2.5 DIETARY INTAKE OF VITAMIN D AND VITAMIN D 
STATUS 
Globally, dietary intake of vitamin D is often estimated to be low, as only a few 
foods naturally contain vitamin D. This is not a problem unless UVB exposure 
is also low. Poor vitamin D status is a concern in many parts of the world, 
especially in northern latitudes with limited sunlight or in regions where the 
population covers most of their skin with clothing [88, 118]. Vitamin D status 
is measured by circulating 25(OH)D concentrations, which is also the 
biochemical indicator for dietary vitamin D intake. 
Dietary intake of vitamin D varies considerably even within Europe, from 
a mean daily intake of 2 μg in Spanish women to 10 μg in Norwegian women 
[119]; in Northern Europe, it varies from 4 to 14 μg [88]. These dissimilarities 
are due to different dietary patterns (DP), recommendations about vitamin D 
intake and supplementation, food fortification strategies, dietary assessment 
methods, and different approaches in accounting in supplemental vitamin D 
intake [119]. 
Vitamin D status also varies among the European population. Lips et al., 
employing unstandardized prevalence figures, reported that 7–62% of the 
European population had 25(OH)D below 50 nmol/l [88]. Some of the large 
variation in prevalence figures are due to methodological differences in 
25(OH)D assessment (see section 2.1.6). Utilizing standardized 25(OH)D 
values, including Finnish data, Cashman et al. have estimated that 13% of 
Europeans suffer from vitamin D deficiency as determined by 25(OH)D <30 
nmol/l [74]. Furthermore, the risk of vitamin D deficiency was multifold in 
dark-skinned ethnic subgroups [74]. In Finland, 56–90% of dark-skinned 
women had 25(OH)D <50 nmol/l [120-122].  
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2.5.1 MATERNAL VITAMIN D INTAKE AND STATUS  
Many experts recommend maternal vitamin D supplementation to achieve 
adequate vitamin D intake, although consensus is lacking [123, 124]. Maternal 
vitamin D deficiency has been associated with adverse pregnancy outcomes 
[17, 125]. In Europe, the unstandardized prevalence of 25(OH)D <50 nmol/l 
ranged from 18% to 90% in pregnant women [126]. In the literature and in this 
thesis, maternal vitamin D status indicates both serum 25(OH)D during 
pregnancy and UCB 25(OH)D at birth. 
In Canada, pregnant women’s (n=537) total vitamin D intake was 20 
μg/day on average, with the majority coming from supplements [127]. Also, 
their 25(OH)D concentration was relatively high, and only 2% had 25(OH)D 
<50 nmol/l [127]. In a study conducted in the USA (n=321), 25(OH)D was 
below 50 nmol/l in 8–17% of pregnant women [128]. In a cohort of 1050 Irish 
mother-newborn pairs, however, 80% had 25(OH)D <50 nmol/l measured 
from UCB [129]. Of these mothers, 42% used vitamin D supplements during 
pregnancy, and 82% of the supplements contained 5 μg vitamin D [129].  
Among Norwegian pregnant women (n=855), 27–34% had 25(OH)D <50 
nmol/l in 2007–2009 [130]. Their mean daily vitamin D intake was 10.4 μg, 
but the majority of them (59%) still did not reach the recommended intake of 
10 μg [130]. In a large Swedish cohort (n=1985), only 42–43% used vitamin D 
supplements during pregnancy [131]. Altogether, 25% had 25(OH)D <50 
nmol/l. In their study, the corresponding prevalences were 13% in women of 
North European origin and 69–82% in women of Asian and African origin 
[131]. 
Previously, among Finnish pregnant women, vitamin D intake has been 
reported to be below the recommended level, and poor vitamin D status has 
been common. Table 4 shows vitamin D intake and status in Finnish pregnant 
women during the last two decades. In a birth cohort of Type 1 Diabetes 
Prediction and Prevention Study (DIPP), in 1998-1999, the mean intake of 
vitamin D from food was approximately 5 μg/day, and from supplements 
almost 4 μg/day [132]. However, only 40% were supplement users [132]. The 
mean total vitamin D intake of pregnant and breastfeeding women was 6.9 and 
7.3 μg/day in 1998-2004 [133]. In the same cohort, vitamin D intake among 
pregnant women increased from 6.2 μg/day in 1997–2000 to 8.9 μg/day in 
2003–2004 [134]. Within the DIPP study in 1993–2004, 69% of pregnant 
women had 25(OH)D <50 nmol/l [135]. Furthermore, in 1994–2004, 88% of 
mother-newborn pairs had 25(OH)D <50 nmol/l [136].  
In 2007 (n=125), 77% of Finnish pregnant women had 25(OH)D <50 
nmol/l in the first trimester, although the total mean vitamin D intake was 14.3 
μg/day in the third trimester [137] (Table 4). Approximately half of vitamin D 
intake came from supplements, and 80% of women used vitamin D 
supplements [137]. In another sample of 113 mothers, dietary intake of vitamin 
D was 11.1 μg/day in 2010–2011 [138]. A Finnish gestational diabetes 
prevention study (RADIEL) found that the median vitamin D intake from food 
in pregnant women at an increased risk of GDM was 6 μg/day in 2008–2011 
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[139]. Together with supplements, the total median vitamin D intake rose to 
12 μg/day, with 72% of supplement users [139]. In that study, only 30% 
(65/219) of pregnant women had 25(OH)D <50 nmol/l [140]. However, it 
should be mentioned that 56% of these women were obese (body mass index 
[BMI] >30 kg/m2) due to study recruitment criteria, which probably affected 
25(OH)D by decreasing its concentration [140]. Based on the national Infant 
feeding report in 2010 (n=3406), 62% of mothers used some supplements 
during pregnancy, 18% used only vitamin D supplements, and 45% 
multivitamin supplements (which most likely contained vitamin D) [141]. 
Some of the discrepancy between studies may be a result of different 
methodologies in assessing and reporting vitamin D intake. In addition, the 
solar contribution in vitamin D status is difficult to measure and is not 
evaluated in all studies. Vitamin D recommendations have been updated a few 
times during the last two decades to improve vitamin D status in the Finnish 
population. Regarding pregnant and breastfeeding women, the guideline for 
supplementation (10 μg/day) was changed from winter-only to year-round 
supplementation in 2011. Total maternal vitamin D intake has increased, but 
the current vitamin D status of Finnish pregnant women is unknown. 
 
 
Table 4 Vitamin D intake and status among Finnish pregnant women during the last two decades 
Study Year of study N 
Mean intake 
of dietary 
vitamin D, 
μg/day 
Prevalence of 
25(OH)D <50 
nmol/l, % 
Dietary 
assessment 
method 
25(OH)D 
assay 
DIPP [132] 1998–99 797 4.8-6.7  181-item FFQ  
DIPP [134] 
1997–2000 
4880 
6.2  181-item 
FFQ 
 
2003–04 8.9   
DIPP [135] 1993–04 686  69  IDS OCTEIA2 
Viljakainen 
et al. 2010 
[137] 
2007 125 14.3 77 70-item FFQ 
IDS 
OCTEIA2 
RADIEL 
[139] 2008–11 234 12
1  3-day food record  
RADIEL 
[140] 2008–14 219  30  
IDS-
iSYS2 
25(OH)D, 25-hydroxyvitamin D; DIPP, Type 1 Diabetes Prediction and Prevention Study; FFQ, food frequency 
questionnaire; RADIEL, The Finnish Gestational Diabetes Prevention Study 
1 Median 
2 Immunoassay provided by Immunodiagnostic Systems (IDS) 
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2.5.2 INFANT VITAMIN D INTAKE AND STATUS 
 
Infants require vitamin D for normal development and growth. Vitamin status 
of the newborn depends on the maternal vitamin D status. It is presumed that 
the maternal supply for the infant lasts for weeks after birth [142]. However, 
maternal vitamin D status and the infant’s own capacity to utilize possible 
stores of vitamin D metabolites may affect the time period when the supply of 
vitamin D is exhausted. After birth, the infant’s only sources of vitamin D are 
breast milk, infant formula, supplements, and sunlight-induced skin synthesis 
until complementary feeding is started. Globally, vitamin D deficiency is 
common in newborns [126], but in older infants, the situation is less clear.  
Breast milk is the ideal food for the newborn and infant. In Finland, 
breastfeeding is recommended exclusively until 4–6 months, and partially 
until 1 year, or longer if the family prefers. Vitamin D and 25(OH)D pass into 
the breast milk, and the vitamin D content in breast milk relies on the maternal 
vitamin D intake and status [81, 84]. However, only small amounts of vitamin 
D metabolites are secreted into breast milk [143]. Authors of a Danish study 
estimated that infants’ daily median intake of vitamin D and 25(OH)D from 
breast milk was 0.1 and 0.3 μg, respectively, among mothers with sufficient 
vitamin D status [65]. To gain noteworthy vitamin D content in the breast 
milk, a multifold maternal vitamin D supplementation may be required [144, 
145]. Thus, infant vitamin D supplementation is the preferred, safest and most 
effective method to reach sufficient vitamin D status in the infant. 
The role of sunlight exposure in the infant’s vitamin D status is small 
because infants are not generally exposed to sunlight, and it is not even 
recommended due to increased risk of sunburn and skin cancer. This is often 
demonstrated by the lack of seasonal variation in vitamin D status in infants 
compared with older children [146]. Infants are at high risk of vitamin D 
deficiency because of low vitamin D content in breast milk, minimal sun 
exposure, and critical demand for vitamin D for normal growth and bone 
development. Therefore, vitamin D supplementation is required and 
recommended for infants in many parts of the world. 
Infant formulas are fortified with vitamin D, and thus, infants who are 
exclusively breastfed compared with formula-fed infants commonly have 
lower circulating 25(OH)D concentrations. As vitamin D supplementation is 
usually recommended to all infants, infants who consume high amounts of 
infant formula may exceed the UL [147]. In Finland, the current 
recommendation of vitamin D supplementation for infants is adjusted 
according to the consumption of infant formula (see section 2.3). 
Among US primary care patients aged 8–24 months, 12% had 25(OH)D 
below 50 nmol/l in 2005–2007 (n=380) [148]. Of Norwegian infants 9–16 
months old with immigrant backgrounds, 47% had 25(OH)D <50 nmol/l in 
(n=102) [149]. Besides the possibly darker skin pigmentation of immigrants, 
which increases the odds for low 25(OH)D, this high prevalence may also 
indicate socioeconomic factors known to associate with vitamin D status. 
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Among Finnish infants, vitamin D intake was below the recommended 
intake of 10 μg/day two decades ago (Table 5). On the other hand, 
supplementation has been widely accepted in young children. In the DIPP 
study in 1999–2000, 1-year-old infants’ (including partly-breastfed) total 
daily intake of vitamin D was 9.8 μg, of which 4.0 μg was from food [150]. 
However, in 2004, total vitamin D intake had risen to 12.2 μg/day, and of 
supplement users, the supplemental vitamin D intake was 6.8 μg/day (only 
non-breastfed) [151]. In Finnish 1-year-old infants, the main food sources of 
vitamin D intake have been infant formula, dairy products, mass-produced 
baby foods, cereal foods, and fish [150, 152]. 
In young children, vitamin D intake has been shown to decrease with 
increasing age, which has been mainly due to a decline in the proportion of 
supplement usage [150, 151]. The proportion of children who received vitamin 
D supplements was 91%, 81%, and 26% in 3-month-olds, 1-year-olds, and 3-
year-old children, correspondingly [150], and more recently, within the same 
cohort, it was 86% in 1-year-olds [151]. Furthermore, in the DIPP study 
(n=387), 25(OH)D concentration rose 16 nmol/l on average between 1998–
2002 and 2003–2006 among children aged 3 months to 12 years [153]. Mean 
25(OH)D concentrations in that study were 89–91 nmol/l in children under 
the age of 2 years [153]. 
According to the Infant feeding report in 2010, 90% of 1-year-old infants 
received vitamin D supplements [141]. In another study of 86 infants, infants’ 
mean total vitamin D intake was 12 μg/day [154]. Of those infants, 2% had 
25(OH)D <37.5 nmol/l [154]. In a pediatric population of infants under the 
age of 2 years with chronic illness studied between 2007 and 2010, 7% suffered 
from vitamin D deficiency (<37.5 nmol/l) [146]. In a vitamin D 
supplementation trial (VIDI pilot study) conducted in 2010–2011, newborns’ 
mean 25(OH)D was 52 nmol/l, and after 10 μg/day supplementation until 3 
months of age, the mean value increased to 93 nmol/l [138]. 
To conclude, a larger proportion of 1-year-old infants are consuming 
vitamin D supplements, and it seems that vitamin D deficiency is not common 
in infants in Finland. However, considering the fact that vitamin D food 
fortification doubled in 2010, updated data on infant vitamin D intake is 
needed. 
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Table 5 Vitamin D intake in Finnish 1-year-old infants during the last two decades 
Study Year of study N 
Mean total 
intake of 
dietary 
vitamin D1 
Mean intake 
of vitamin D 
from food 
Dietary 
assessment 
method 
DIPP [150] 1999–2000 267 9.8 4 3-day food record 
DIPP/ The Diet of 
Finnish Preschoolers 
2008 [151] 
2004 567 10.2–12.2 5.4 3-day food record 
Viljakainen et al. 
2011 [154] 2009 86
2 12.3 43 3-day food record 
1 Including supplements 
2 Infants were 14 months old 
3 [155] 
 
2.6 MATERNAL DETERMINANTS OF VITAMIN D 
STATUS 
Factors associating with vitamin D status have been vastly studied. Along 
with skin pigmentation, several genetic determinants, also within similar 
ethnic groups, influence vitamin D status [156, 157] and the response of 
vitamin D intake on 25(OH)D concentration [158-160]. Furthermore, besides 
the apparent determinants of vitamin D status, such as UVB exposure, season, 
and total dietary vitamin D intake, certain lifestyle-related factors have been 
identified to associate with 25(OH)D. In short, these lifestyle factors are 
commonly DPs, age, education, BMI, physical activity, and smoking [161-164]. 
Usually, a diet rich in vitamin D but also healthy otherwise correlates with 
25(OH)D [162]. It is often observed that unhealthy lifestyle factors, as well as 
healthy ones, are cumulative, making it difficult to identify the independent 
role of a specific determinant for vitamin D status or for other health 
outcomes. 
In pregnant women, factors similar to non-pregnant adults determine 
25(OH)D levels. Moon et al. studied the tracking of 25(OH)D during 
pregnancy in the UK (n=1753), i.e., the change between early and late 
pregnancy 25(OH)D [165]. In that study, vitamin D supplement use and 
physical activity in late pregnancy enhanced maternal 25(OH)D, while 
gestational weight gain reduced maternal 25(OH)D. Surprisingly, 
prepregnancy BMI or smoking during pregnancy did not associate with 
tracking of 25(OH)D [165]. However, in another study (n=829), Moon et al. 
observed that age had a positive association with 25(OH)D, but BMI, smoking, 
and weight gain had an inverse association[166].  
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According to Perreault et al. in Canadian pregnant women (n=523), the 
strongest factors related to maternal 25(OH)D were ethnicity, season, and 
prepregnancy BMI, but dietary intake of vitamin D played an oddly lesser role 
in vitamin D status [167]. As Perreault et al. in Canada, Sauder et al. (n=605) 
in the USA identified collateral factors, except vitamin D intake also 
significantly modified maternal 25(OH)D [168]. 
In some studies, parity has been observed to associate with maternal 
vitamin D status [169, 170]. In a Danish cohort (n=2082), vitamin D 
supplementation was a significant determinant of maternal 25(OH)D, and 
multiparity was detected as a risk factor for not taking vitamin D supplements 
[171]. Maternal age has also been identified as a negative determinant for UCB 
25(OH)D in Greece (n=60), which was recognized to be a result of increased 
UVB exposure in younger pregnant women compared to older ones [172].  
 
2.7 MATERNAL VITAMIN D AND GDM 
To ensure adequate glucose and energy supply for the fetus in normal 
pregnancy, insulin resistance is developed, and gluconeogenesis is increased 
in the liver. Further, fasting glucose levels are decreased, but postprandial 
glucose levels are elevated [173]. To compensate for insulin resistance, insulin 
secretion is increased in pregnancy. In GDM, a type of diabetes that is 
diagnosed during pregnancy and disappears after pregnancy, this system is 
impaired, and hyperglycemia evolves [174]. Definition and glucose thresholds 
of diagnosis vary, but they are usually based on an oral glucose tolerance test 
(OGTT), with one or more values exceeding the thresholds [175, 176]. Globally, 
GDM prevalences vary around 1–14% [177] and in Europe around 1.5–10% 
[178]. GDM prevalence has been rising globally, alongside obesity [179]. Also, 
the older age of parturients is one reason for increased GDM incidence [180, 
181]. In Europe [175] and in Finland, GDM is the most common pregnancy 
complication. In Finland in 2014, 11% of pregnant women were diagnosed with 
GDM [182]. In 2017, the corresponding figure was 16% [183]. 
GDM has detrimental consequences for the offspring, such as macrosomia 
[184], increased odds for obesity and diabetes later in life [19, 185, 186], in 
addition to possible consequences for the mother herself, such as diabetes and 
hypertension [19, 187]. Adverse associations between maternal glucose levels 
and pregnancy outcomes have also been observed without the diagnosis of 
GDM [188, 189]. Hence, potential underlying factors for hyperglycemia during 
pregnancy have been investigated along with vitamin D. 
Low maternal 25(OH)D has been associated with adverse pregnancy 
outcomes, including pre-eclampsia, bacterial vaginosis, and GDM [190, 191]. 
Lower maternal 25(OH)D has also been associated with increased risk of GDM 
in numerous meta-analyses (Table 6) [17, 124, 192-195]. Observational studies 
and meta-analyses utilizing those studies have been criticized for not taking 
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into account the relevant confounders such as maternal BMI [196]. In the most 
recent meta-analysis studying the association between maternal 25(OH)D and 
GDM by Amraei et al., the authors concluded that lower 25(OH)D increased 
the risk of GDM [195]. This result remained after stratifying studies by regions 
[195]. 
A meta-analysis employing 5 randomized clinical trials (RCT) of vitamin D 
supplementation during pregnancy by Roth et al. concluded that vitamin D 
supplementation could reduce the risk of GDM [125], contrary to an older 
meta-analysis [197], although the researchers considered the RCTs to be of low 
quality [125]. A new Cochrane review estimated with moderate evidence that 
maternal vitamin D supplementation decreased the risk of GDM based on 4 
RCTs [198]. 
Many meta-analyses face a problem of heterogeneity [193]. Different study 
locations have varying prevalences of vitamin D deficiency as well as GDM and 
obesity. In light of these issues, high variability in adjusting for covariates [17, 
195] and varying thresholds applied in GDM diagnosis [178] and for vitamin 
D deficiency [195] further produces limitations for the interpretation of the 
results. On the other hand, meta-analyses, if conducted appropriately, 
produce higher levels of evidence compared with a single study. 
In women already diagnosed with GDM, vitamin D supplementation has 
not improved glucose metabolism based on a meta-analysis by Rodrigues et 
al. [199], but not all agree [200]. The possible mechanisms for how vitamin D 
could affect glucose metabolism are by improving insulin sensitivity [201] or 
stabilizing beta cell function [202, 203]. To summarize, vitamin D deficiency 
could probably increase the possibility of GDM, but this is uncertain since 
results are often confounded [192, 196]. 
 
 
 
  
Table 6. Results of latest systematic reviews and meta-analyses based on observational studies about maternal 
vitamin D status and GDM 
Publication Maternal determinant N of studies Risk of GDM Heterogeneity 
Amraei et al. 
2018 [195] 
vitamin D deficiency with no defined 
25(OH)D cut-off, 26 + no, mean difference of 25(OH)D 
between GDM and non-GDM 
yes 
Lu et al. 2016 
[192] 
vitamin D insufficiency with 25(OH)D 
cut-offs of 50 or 75 nmol/l 20 + yes 
Zhang et al. 
2015 [193] 
vitamin D deficiency with 25(OH)D 
cut-off of 50 nmol/l, 20 + no, mean difference of 25(OH)D 
between GDM and non-GDM 
yes 
Harvey et al. 
20141 [124] 25(OH)D 8 NS - 
Aghajafari et al. 
2013 [17] 
vitamin D insufficiency with 25(OH)D 
cut-offs of 50 or 75 nmol/l 10 + no 
Poel et al. 2012 
[194] 
vitamin D deficiency with 25(OH)D 
cut-off of 50 nmol/l, 7 + no, mean difference of 25(OH)D 
between GDM and non-GDM 
yes 
GDM, gestational diabetes mellitus; 25(OH)D, 25-hydroxyvitamin D; + indicates an association between low vitamin D status and 
increased risk of GDM; NS, non-significant 
1 systematic review without meta-analysis 
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2.8 VITAMIN D AND INFANT GROWTH 
Fetal and infant growth is intense and, therefore, especially sensitive for 
environmental adverse effects such as nutritional inadequacies. An infant 
gains an average of 25 cm in length during the first year of life, as compared 
with the yearly growth of 6 cm later in childhood [204]. Fetal and infant 
growth are regulated by several hormonal factors in the systemic endocrine 
network and locally in the growth plate, but the specific mechanisms are still 
not completely understood. The main growth-regulating hormones during the 
fetal period are insulin and insulin-like growth factors (IGF), and in infancy, 
they are growth hormone, IGF-1, fibroblast growth factors, thyroxine, and sex 
steroids. Linear growth (i.e., length/height) is dependent on skeletal growth. 
Thus, one could assume that vitamin D has a role in linear growth while 
acknowledging the significant role in normal bone development. 
Already in early 1900, it was suggested that more rapid weight gain in 
children was related to sunshine or vitamin D [205]. Stearns and colleagues 
examined an optimal dose of vitamin D in relation to infant length (n=36), and 
they observed that increased linear growth was seen in infants who were fed 1 
teaspoon of cod liver oil daily (containing roughly 10 μg of vitamin D) 
compared with infants given approximately a fourth of that amount [205]. 
They continued with their research and found that a much larger dose of 
vitamin D (45–115 μg) decreased infants’ (n=9) linear growth [206]. Despite 
the small number of infants in these early studies, which has raised well-
deserved criticisms, the findings have left a mark in vitamin D history by 
prompting a general cautiousness against vitamin D fortification and 
supplementation [207]. An exception for this has been Finland, where high 
doses have been recommended in the past [104]. 
Studies examining the relationship between vitamin D and infant growth 
are scarce and their results conflicting. In rickets, stunted growth or slow 
linear growth is perceived as one of the symptoms. However, in many cases of 
rickets, the patient may suffer from other nutrient deficiencies or illnesses as 
well, possibly in addition to other poor living conditions. Indeed, it has been 
suggested that the effect of severe vitamin D deficiency on growth is secondary, 
as deficient status probably increases the risk of infectious diseases, which are 
known to restrict growth. Consequently, it is difficult to recognize the 
independent role of vitamin D in the regulation of growth. In a case report 
from the USA, an inherited 25-hydroxylase deficiency lead to rickets and 
stunted growth in a Caucasian child [208]. This condition was successfully 
treated with 1,25(OH)2D [208]. Generally, it is assumed that vitamin D 
supplementation or higher vitamin D status in either the mother or infant 
promotes infant growth also without the presence of rickets. 
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2.8.1 MATERNAL VITAMIN D AND INFANT PRENATAL GROWTH 
There have been quite a lot of reviews and meta-analyses about the effect of 
vitamin D supplementation during pregnancy on birth size [124, 197, 198, 209-
212]. The results are presented in Table 7. The meta-analysis by Bi et al. 
concluded that maternal vitamin D supplementation decreased the risk of SGA 
and increased birth weight, but no association was observed with birth length 
or head circumference [209]. Roth et al. came to similar conclusions but 
emphasized the low quality of RCTs (Table 7) [125]. An updated Cochrane 
review concluded with moderate evidence that maternal vitamin D 
supplementation decreased the risk of low birth weight (<2500 g) based on 5 
RCTs [198]. 
To study 25(OH)D rather than vitamin D supplementation against a health 
outcome has a strength: it overcomes challenges in estimating dietary intakes 
and cutaneous synthesis, although the causality remains unanswered. 
According to a meta-analysis by Aghajafari et al., maternal 25(OH)D <37.5 
nmol/l increased the risk of SGA compared with maternal 25(OH)D >37.5 
nmol/l (Table 7) [17]. According to a more recent meta-analysis by Tous et al., 
mothers with 25(OH)D <30 nmol/l had newborns with lower weight and head 
circumference but not length compared with mothers with >30 nmol/l [213]. 
Furthermore, no relation was detected with a cut-off of 50 nmol/l or 75 nmol/l 
[213]. Nonetheless, based on a Mendelian randomization study with known 
genetic variants associating with 25(OH)D, no evidence for an effect of 
maternal 25(OH)D on birth weight was observed [18]. 
A problem again in the meta-analyses can be the high heterogeneity 
between included studies [213, 214]. The single studies are carried out in 
different geographical areas, leading to inconsistencies related to, for example, 
sunlight exposure, ethnicity, DPs, supplementation policy, baseline vitamin D 
status, and overall nutritional status. In addition, different study protocols, for 
example, a wide variation in the supplementation procedure (20–125 μg/day, 
875–1250 μg/week, 1250 μg/4 days, 1500 μg/month/2 months, or single bolus 
dose of 1500–5000 μg versus placebo or a standard treatment/10 μg/day) and 
different 25(OH)D cut-offs applied can create challenges in data analysis [209, 
213]. 
Exploring this topic from a Scandinavian perspective, the results appear to 
be equally inconsistent as from a global point of view. In a Norwegian study 
(n=719, mean 25(OH)D 50 nmol/l, included in the Tous et al. meta-analysis), 
after adjusting for ethnicity, there was no relation between maternal vitamin 
D status and birth size [215]. In a Danish study, applying two cohorts with 
Caucasian women (n=1038, mean 18–22 nmol/l, included in Tous et al.), UCB 
25(OH)D was not associated with weight or head circumference but was 
associated positively with infant length at age 2 weeks [216]. In another Danish 
cohort (n=2082, mean 65–79 nmol/l), Lykkedegn et al. observed no 
association between 25(OH)D measured at three time points during 
pregnancy and birth weight [171]. But in that study, UCB 25(OH)D (mean 47 
nmol/l) correlated positively with birth weight, surprisingly indicating a U-
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shaped association, i.e., both low and high UCB 25(OH)D values associated 
with higher birth weight [171]. In a recent cohort of Swedish women (n=2052, 
mean 25(OH)D 64–75 nmol/l, included in Tous et al.), mothers with 25(OH)D 
≥100 nmol/l and 30–49.9 nmol/l were at decreased risk for having a low birth 
weight infant compared with mothers with 25(OH)D <30 nmol/l [217]. These 
associations existed when 25(OH)D measurements were conducted in the 
third trimester but not in the first trimester. In this cohort, ethnicity may have 
been a confounder as in the <30 nmol/l category only 14% of the women were 
born in Sweden compared with 94% in the ≥100 nmol/l category [217]. In 
Finland, there have been very few studies on maternal 25(OH)D and infant 
growth, but in one study by Viljakainen et al. (n=124, median 43 nmol/l), no 
association between maternal 25(OH)D and birth size was observed [154]. 
To summarize, there are inconsistencies in studies examining the 
relationship between maternal vitamin D status and birth size. However, 
severe maternal vitamin D deficiency probably increases the risk of lower birth 
weight, and correction of the deficient status, i.e., with vitamin D 
supplementation, decreases the risk of low birth weight, but for birth length 
and other birth size measures, the relationship is inconclusive.
 Table 7. Results of the latest meta-analyses of RCTs and observational studies examining the association between maternal vitamin D 
supplementation and vitamin D status and birth size 
  Length/Height Weight Head circumference 
Publication Maternal determinant 
Effect/ 
association 
N of studies, 
heterogeneity 
Effect/ 
association 
N of studies, 
heterogeneity 
Effect/ 
association 
N of studies, 
heterogeneity 
Maugeri et al. 
2019 [210] 
vitamin D 
supplementation + 7, yes + 12, no + 6, no 
Bi et al. 2018 
[209] 
vitamin D 
supplementation NS 12, yes + 17, yes NS 11, yes 
Roth et al. 2017 
[125] 
vitamin D 
supplementation NS 19, yes + 30, yes NS 17, yes 
Perez-Lopez et 
al. 2015 [212] 
vitamin D 
supplementation + 2, yes + 5, yes NI - 
Thorne-Lyman 
et al. 2012 [211] 
vitamin D 
supplementation NS 2, yes NS 5, yes NI - 
Tous et al. 2019 
[213] 
25(OH)D cut-offs of 
30, 50 and 75 nmol/l NS 4, yes + 
1 15, yes + 1 7, yes 
Santamaria et 
al. 2018 [214] 
25(OH)D cut-offs of 
25, 27.5, 28, 30 and 
50 nmol/l 
NS 10, yes + 16, yes NS 7, yes 
Aghajafari et al. 
2013 [17] 
25(OH)D <37.5 vs 
>37.5 NS 2, not reported + 4, not reported NS 2, not reported 
RCT, randomized controlled trial; 25(OH)D, 25-hydroxyvitamin D; + indicates a positive effect of vitamin D supplementation or an association of higher 25(OH)D toward 
newborn growth; NS, non-significant; NI, not investigated  
1 with cut-off of 30 nmol  
40
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2.8.2 MATERNAL VITAMIN D AND INFANT POSTNATAL GROWTH 
Research related to maternal vitamin D and pregnancy and birth outcomes is 
mounting, but fewer studies have investigated vitamin D and postnatal 
outcomes. Naturally, it is of interest as to whether the possible effect of 
maternal vitamin D on birth size persists into later infancy and childhood. 
Table 8 presents original studies that have investigated the association 
between maternal 25(OH)D and infant postnatal growth. 
The meta-analysis by Bi et al. examined maternal vitamin D 
supplementation in regard to postnatal growth parameters and found three 
studies, involving only subjects of Asian origin [209]. In that study, maternal 
vitamin D supplementation increased weight at 3, 6, 9, and 12 months, height 
at 3, 9, and 12 but not at 6 months, and head circumference at 3 months but 
not at 6, 9, and 12 months [209]. However, a large vitamin D supplementation 
trial conducted in Bangladesh (n=1300, 5 groups of supplementations from 
placebo to 700 μg/week pre- and postnatally), not included in the meta-
analysis of Bi et al., found no effect of maternal vitamin D supplementation on 
infant growth until 1 year of age [218]. In this RCT, a dose-dependent effect on 
25(OH)D (mean between 24 and 110 nmol/l) was achieved in a study 
population with an originally high prevalence of vitamin D deficiency [218].   
In a study conducted in the USA, pregnant women with 25(OH)D above 30 
nmol/l had heavier and taller 4-month-old infants compared with women with 
<30 nmol/l, although the relationships attenuated to some extent at 1 year of 
age [219] (Table 8). Few studies have not found an association between 
maternal vitamin D status and child growth or body composition at infancy 
[168, 220-224], and some have observed both positive and negative 
associations  [225] (Table 8). A meta-analysis by Santamaria et al. employed 
4 observational studies with maternal 25(OH)D as a determinant for infant 
postnatal growth, ([219, 220, 225, 226], included in Table 8 below) [214]. They 
concluded that low vitamin D status was associated with higher weight at 9 
months (2 studies) but smaller head circumference at 1 year of age (2 studies) 
and no association for length (4 studies) [214]. 
Overall, studies on maternal vitamin D and postnatal growth are 
conflicting. Also, adjustment procedures vary between studies from zero 
adjustments [227] to adjustments for up to 11 variables [225], which further 
complicates comparisons between the studies.  
 Table 8 Summary of the negative (-) and positive (+) relationships between higher maternal 25(OH)D concentration and infant postnatal growth in original studies 
    Anthropometric outcomes 
Publication, country, year 
of the study Design, N 
Mean 
25(OH)D, 
nmol/l 
Applied cut-offs for 
25(OH)D, nmol/l Length/Height Weight 
Head 
circumference Other 
Eckhardt et al. 2015, 
USA, 1959–1965 [219] 
cohort, 
2438 mothers, 
2473 infants 
59 <30 vs. ≥30 + 4, 12 mo + 4 mo NS 12 mo + 4, 12 mo NS BMIZ 
Neelon et al. 2018, USA, 
2009–2012 [228] cohort, 211 41 quartiles NI - 12 mo NI - BMIZ 3 years 
Sauder et al. 2017, USA, 
2009–2014 [168] cohort, 348 56 
continuous UCB 
25(OH)D NI NS 5 mo NI 
NS fat and fat-free 
mass 
Leffelaar et al. 2010, 
Netherlands, 2003–2004 
[225] 
cohort, 2739 541 ≤29.9 vs. ≥50 
+ 1 mo 
- 12 mo 
NS 3, 6, 9 mo 
- 6, 9 mo 
NS 1, 3, 12 mo NI  
Javaid et al. 2006 and 
Gale et al. 2008, UK, 
1991–1992 [220, 229] 
cohort, 440 501 <30 vs. 30–50 vs. 50–75 vs. >75 NS 9 mo NS 9 mo NS 9 mo 
NS MUAC, BMI, fat 
and lean mass 
+ bone measures at 
9 years 
NS for other at 9 
years 
Egge et al. 2017, 
Denmark, 2010–2012 
[221] 
cohort, 1780 47-66 
continuous and 
quartiles of 
pregnancy and UCB 
25(OH)D 
NI NI NS 3, 6 mo NS cranial measures 
Vieth Streym et al. 2013, 
Denmark, 2008–2011 
[222] 
cohort, 107 43-73 
continuous 
pregnancy and UCB 
25(OH)D 
NS 4, 9 mo NS 4, 9 mo NI  
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Table 8 continues. 
Gould et al. 2017, 
Australia, 2006–2010 
[226] 
secondary 
analysis of DHA 
supplementation 
trial, 323 
56 
continuous and UCB 
25(OH)D <25 vs. 
25–50 vs. >50  
NS 18 mo NS 18 mo + 18 mo 
+ head 
circumference at 4 
years 
NS for other at 4 
years 
Hanieh et al. 2014, 
Vietnam, 2010–2012 
[230] 
cohort, 960 71 continuous - 6 mo NS 6 mo NS 6 mo  
Prentice et al. 2009, 
Gambia, 1995–2000, 
[223] 
secondary 
analysis of 
calcium 
supplementation 
trial, 125 
103-111 continuous and <80 vs. >80 NS 3, 12 mo NS 3, 12 mo NS 3, 12 mo  
Ong et al. 2016, 
Singapore, 2009–2011 
[224] 
cohort, 807 81 <50 vs. 50–74.9 vs. >75 
NS 3, 6, 9, 12 
mo 
NS 3, 6, 9, 12 
mo 
NS 3, 6, 9, 12 
mo 
NS MUAC, 
abdominal 
circumference, BMI, 
skinfolds 
NS 15, 18, 24 mo 
Chi et al. 2018, China, 
2014–2015 [227] cohort, 160 31-65 
continuous and <50 
vs ≥50 pregnancy 
and UCB 25(OH)D 
+ 6 mo + 6 mo + 6 mo  
Roth et al. 2013 excluded due to insufficient data [231]. 
25(OH)D, 25-hydroxyvitamin D; mo, months; NS, non-significant; NI, not investigated; BMI, body mass index; BMIZ, BMI-for-age score; UCB, umbilical cord blood; MUAC, mid-upper-arm 
circumference; DHA, docosahexaenoic acid  
1 median 
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2.8.3 INFANT VITAMIN D AND GROWTH 
Surprisingly few studies have examined infants’ own vitamin D status in 
relation to growth. Table 9 summarizes the original studies on infant vitamin 
D and growth. In a small RCT among Canadian infants by Gallo et al., subjects 
were randomized to receive a daily vitamin D supplementation dose of 10, 20, 
30, and 40 μg from 1 month until 1 year [232]. They found no differences in 
growth parameters between groups despite a dose-response effect on infants’ 
vitamin D status (Table 9). In this study, the intervention was discontinued in 
the 40 μg group due to 25(OH)D values exceeding 250 nmol/l [232]. A follow-
up study of these infants at the age of 3 years (n=87/132) confirmed no 
difference in growth patterns [233]. Similarly, in Finland, Holmlund-Suila et 
al. conducted an RCT in 113 newborns until they were 3 months old [138]. 
Infant 25(OH)D values rose from median 53 nmol/l to mean 88, 124 and 153 
nmol/l according to supplementation groups of 10, 30, and 40 μg, respectively. 
There were no differences between groups in length, weight, head 
circumference, or leg length at 3 months of age [138]. 
In another RCT among Indian low–birth weight infants with a high 
prevalence of vitamin D deficiency, vitamin D supplementation of 35 μg/week 
(n=1039) from the age of 1 week until 6 months improved infant length, 
weight, and MUAC at 6 months compared with placebo (n=1040) [234] (Table 
9). The mean 25(OH)D in the supplemented infants was 55 nmol/l (n=216), 
and in infants receiving placebo, it was 36 nmol/l (n=237). In this study, 38% 
were lost to follow-up at 6 months and even more from 25(OH)D analyses 
[234]. In a follow-up at 3–6 years of age, no effect was observed in length and 
weight (when mean 25(OH)D were 32–34 nmol/l) [235]. However, the 
supplemented children were thinner at 3–6 years old [235]. An Ecuadorian 
vitamin A and zinc trial reported that stunting was more common among 
children 6–36 months old with 25(OH)D <42.5 nmol/l compared to those with 
≥42.5 nmol/l [236]. These children had an overall high prevalence of stunting 
(62%) and low socioeconomic status [236]. 
Among Danish 9-month-old infants, 25(OH)D correlated inversely with 
BMI, waist circumference, and length [237] (Table 9). Within a large Finnish 
prospective birth cohort (n=10 060), Hyppönen et al. investigated whether 
infant vitamin D supplementation had long-term consequences on height at 1 
and 14 years of age and on adult height [207]. They concluded that either 
vitamin D supplementation of <50, 50 (the recommendation at the time) or 
>50 μg/day, or supplementation categorized as none, irregular, or regular use 
were associated with heights at any age. However, a small number of 
participants in the “none vitamin D supplementation” (n=20–31) group may 
have constrained the analysis [207]. 
To conclude, the data concerning vitamin D and infant growth are scarce, 
and no definite deduction can be made.  
  
 Table 9 Summary of the negative (-) and positive (+) relationships between infant vitamin D and infant growth in original studies 
Publication, 
country, year of the 
study 
Design, N 
Mean baseline 
25(OH)D, 
nmol/l 
Exposure Length/ Height Weight 
Head 
circumference Other 
Gallo et al. 2013 
and 2016, Canada, 
2007–2011 [232, 
233] 
RCT, 132 51-62 10, 20, 30 and 40 μg/day 
NS 1, 2, 3, 
6, 9, 12 
mo 
NS 1, 2, 
3, 6, 9, 12 
mo 
NS 1, 2, 3, 6, 
9, 12 mo NS at 3 years  
Kumar et al. 2011 
and 2015, India, 
2007–2010 [234, 
235] 
RCT, 2079 NI placebo and 35 μg/week + 6 mo + 6 mo1 NS 6 mo 
+ MUAC 6 mo; - 
BMIZ, MUAC at 3–6 
years; NS for other at 
3–6 years 
Mokhtar et al. 
2018, Ecuador, 
2000–20032 [236] 
secondary cross-
sectional analysis 
of vitamin A and 
zinc trial, 516 
58 25(OH)D <42.5 vs. ≥42.5 nmol/l + 6-36 mo 
+ 6-36 
mo NI  
Arnberg et al. 
2011, Denmark, 
2007–2008 [237] 
cross-sectional, 
255 77 continuous 25(OH)D - 9 mo NI NI 
- BMI, waist 
circumference 
Holmlund-Suila et 
al. 2012, Finland, 
2010–2011 [138] 
RCT, 113 533 10, 30, and 40 μg/day NS 3 mo NS 3 mo NS 3 mo NS bone measures 
Hyppönen et al. 
2011, Finland, 
1967–1998 [207] 
cohort, 10 060 NI 
<50 vs. 50 vs. >50 
μg/day, and none vs. 
irregular vs. regular use 
of vitamin D 
supplementation at 1 
year of age 
NS 12 mo NI NI 
NS height at 14 
years and in 
adulthood 
Greer et al., Chan et al. and Ala-houhala et al. [238-240] excluded due to small numbers of subjects and data availability. 
25(OH)D, 25-hydroxyvitamin D; RCT, randomized controlled trial; mo, months; NI, not investigated; NS, non-significant; BMI, body mass index; BMIZ, BMI-for-age score; MUAC, mid-upper-arm 
circumference 
1 NS in weight-z-score 2 70% of subjects were >12 months old 3 Median. 
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3 AIMS OF THE STUDY 
The main objective of this study was to investigate whether maternal or infant 
vitamin D status associate with fetal and infant growth. The specific aims of 
the thesis were:  
 
I To define maternal and newborn 25(OH)D concentration and to 
characterize maternal determinants of vitamin D status during 
pregnancy. 
 
II To examine if vitamin D status differs between mothers with and 
without GDM. 
 
III To describe vitamin D intake from food and identify food sources of 
vitamin D in 1-year-old infants. 
 
II–IV To investigate whether maternal or infant vitamin D status associate 
with pre- and postnatal infant growth. 
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4 SUBJECTS AND METHODS 
4.1 STUDY DESIGN 
This thesis is part of the VIDI study. The VIDI study was a double-blinded 
intervention study in infants comparing the health effects of a recommended 
(10 μg) and a higher daily dose (30 μg) of supplemental vitamin D3 in infants 
from 2 weeks until 2 years of age [241, 242]. VIDI included three study visits 
of the infant at ages 6, 12, and 24 months. The study recruitment started in 
January 2013, and the last study visit was in June 2016. This thesis employs 
data from pregnancy until the infant is 1 year old, without information on the 
infant’s dose of vitamin D supplementation. 
4.2 RECRUITMENT AND SUBJECTS 
At Kätilöopisto Maternity Hospital in Helsinki, Finland, 987 families were 
recruited into the VIDI study between January 2013 and June 2014 after 
delivery during the mother’s hospital stay. Mothers were of Northern 
European origin without regular medication and with a singleton pregnancy. 
The infants, 492 girls and 495 boys, were born at term (37.0–42.0 weeks) with 
birth weights appropriate for gestational age (birth weight SD score between -
2.0 and +2.0). Exclusion criteria for the newborns were nasal continuous 
positive airway pressure treatment, a need for a nasogastric tube for more than 
one day, intravenous glucose infusion, seizures, and duration of phototherapy 
for more than three days. 
Of the informed eligible families, 29% (987/3408) agreed to participate in 
the VIDI study (Figure 2). In Figure 2 and Table 10, the data- and study-
specific number of subjects and the inclusion and exclusion criteria are shown. 
The number of subjects varies between Studies I–IV due to different data 
applied and different study-specific inclusion criteria. In Study I, the number 
of subjects was 584 as they had complete data on baseline background 
information including maternal food frequencies. In Study II, the number of 
subjects was 723 as they had data on the prenatal clinic record or baseline 
background information. Some missing background information was imputed 
in Study II. In both Studies I and II, subjects had full data on pregnancy and 
UCB 25(OH)D concentrations but without 25(OH)D outliers. In Studies II and 
IV, subjects with congenital disease were excluded. In Study III, the number 
of subjects was 739 as they had complete data on food consumption. In Study 
IV, the number of subjects was 798 as they had data on infant 25(OH)D 
concentration at 1 year of age and body size measurements at 6 months and 1 
year of age. Missing background information was multiple imputed, and 
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subjects not meeting the VIDI study inclusion criteria were excluded in Study 
IV. 
Written informed consent was collected from the parents at recruitment. 
This study was conducted according to the guidelines laid down in the 
Declaration of Helsinki. Ethical approval was obtained from the Research 
Ethics Committee of the Hospital District of Helsinki and Uusimaa 
(107/13/03/03/2012). The project protocol is registered in ClinicalTrials.gov 
(NCT01723852). 
 
Table 10 Number of subjects in Studies I–IV and the basis for subject inclusion and exclusion 
Study N Inclusion criteria Exclusion 
I 
584 
mother-
infant pairs 
Available data on the complete baseline 
background questionnaire including FFQ, 
and early pregnancy and UCB 25(OH)D 
concentrations. 
25(OH)D outliers (n=9) 
II 
723 
mother-
infant pairs 
Available data on the prenatal clinic record 
or baseline background questionnaire, and 
pregnancy and UCB 25(OH)D 
concentrations. 
25(OH)D outliers (n=18), 
pregnancy samples in the 
third trimester (n=2), infants 
with congenital disease 
(n=2) 
III 739 infants Available data on the complete infant food record at 1 year of age. - 
IV 798 infants 
Available data on infant 25(OH)D 
concentrations at 1 year of age, and body 
size measurements at 6 months and 1 
year of age. 
Not meeting the VIDI study 
inclusion criteria (n=12), 
infant with congenital 
disease (n=1) 
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Figure 2 Flow chart on VIDI study recruitment, and available data and number of participants in 
Studies I–IV. 
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4.3 METHODS 
4.3.1 MATERNAL AND FAMILY BACKGROUND FACTORS (I–IV) 
Maternal and family data were obtained using self-administered 
questionnaires, filled in after delivery and when the child was 2 years old, and 
from medical records. Maternal height (cm) and weight (kg) before pregnancy 
and parity were collected primarily from the prenatal record or, if missing, 
from our baseline questionnaire in Studies II and IV. For Study I, the data 
originated solely from the baseline questionnaire. Paternal height, weight, and 
BMI were attained from the baseline questionnaire. The prepregnancy body 
mass index (BMI) (kg/m2) was categorized as underweight (<18.5), normal 
weight (18.5–24.9), overweight (25.0–29.9), and obese (>30.0). The duration 
of gestation was determined from a first-trimester ultrasound examination 
and recorded retrospectively from prenatal records.  
Prepregnancy weight and weight recorded in prenatal clinics were utilised 
to calculate gestational weight gain (GWG) (kg) (II). GWG was recorded at five 
time points during pregnancy from first measurement until last measurement. 
Total GWG was categorised into inadequate, adequate and excessive based on 
national recommendations by prepregnancy BMI: recommended GWG for 
underweight mothers was 12.5-18.0 kg, for normal weight 11.5-16.0 kg, for 
overweight 7.0–11.5 kg, and for obese 5.0–9.0 kg [243]. Parity was determined 
by the number of biological children from the baseline questionnaire or the 
prenatal record and then categorized (primipara/nullipara, secundipara, and 
multipara). 
Maternal use of vitamin D supplements, specific brand names, dosing, and 
date of commencement were recorded (Studies I and II). We calculated the 
average daily intake of vitamin D from supplementation during the last two 
months of pregnancy. 
Maternal history of physical activity before pregnancy was obtained as 
guided and unsupervised exercise and active commuting to work, but only 
guided exercise (minutes per day) was chosen for analysis due to collinearity 
issues (hereafter referred to as physical activity). Parental smoking was 
assessed from questionnaires as the number of daily cigarettes before 
pregnancy (prepregnancy), after delivery, and when the child was 2 years old 
(current), and it was then categorized as a dichotomous variable. Alcohol 
consumption before pregnancy was assessed by the number of dosages per 
week. The family’s income level was gathered via questionnaire, which was 
completed when the child was 2 years old. 
Education level was graded from 1 (=comprehensive school/lower 
secondary education) to 6 (university degree/first or second stage of tertiary 
education). It was then re-categorized into “lower” and “higher” education 
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(lower = lower or upper secondary or post-secondary non-tertiary 
education/less than a bachelor’s degree, higher = first or second stage of 
tertiary education/at least a bachelor’s degree). Parental education was 
defined according to the parents’ highest degree received. 
4.3.2 25(OH)D CONCENTRATION (I, II, IV) 
Maternal pregnancy serum samples were collected at prenatal clinics on 
average at gestational week 11, between June 2012 and February 2014, as part 
of the mothers’ normal follow-ups. Samples were stored in the Finnish 
Maternity Cohort serum bank, which is organized by the National Institute for 
Health and Welfare. UCB samples were obtained at birth between January 
2013 and June 2014. At the 1-year follow-up visit, infant serum samples were 
obtained between December 2013 and June 2015. Study covered all seasons 
and seasonal variation of 25(OH)D were considered in statistical analyses.  
The UCB plasma and pregnancy serum 25(OH)D were analyzed 
simultaneously, and infant serum 25(OH)D in a separate series using the IDS-
iSYS fully automated immunoassay system with chemiluminescence detection 
(Immunodiagnostic Systems Ltd., Bolton, UK). The 25(OH)D value derived 
with this method represents combined 25(OH)D2 and 25(OH)D3. The intra-
assay variations were <13% for UCB samples and <5% for pregnancy and 
infant samples. The quality and accuracy of the serum 25(OH)D analysis are 
validated on an ongoing basis by participation in the vitamin D External 
Quality Assessment Scheme (DEQAS, Charing Cross Hospital, London UK). 
The method showed a constant ≤10% positive bias against the NIST Reference 
Measurement Procedure. 
Plasma UCB 25(OH)D concentrations were corrected with formula 19.13 + 
0.897 * UCB 25(OH)D to be comparable with pregnancy serum 25(OH)D 
concentrations. The equation is based on the comparison of paired 25(OH)D 
measurements in plasma and serum UCB samples in 84 subjects at birth. In 
Studies II and IV, UCB and pregnancy 25(OH)D concentrations were further 
corrected by applying a linear regression equation (correct value 
(nmol/l)=[(initial value)–8.2]/0.99) provided by the manufacturer due to 
methodological changes in the IDS-iSYS system between 2014 and 2016.  
We employed UCB 25(OH)D to reflect both the mother’s vitamin D status 
at the end of pregnancy and the newborn’s vitamin D status at birth. Maternal 
25(OH)D refers to both 25(OH)D measured during pregnancy and UCB 
25(OH)D measured at birth. In Study I, pregnancy 25(OH)D values were 
restricted to subjects sampled at early pregnancy (until 13 weeks of gestation). 
We defined vitamin D sufficiency as 25(OH)D ≥50 nmol/l [71, 114]. Other 
25(OH)D cut-offs used in this thesis were 75 nmol/l based on possible optimal 
bone health [117] and 125 nmol/l based on possible health risks [114]. In the 
original publication of Study II, a threshold of 80 nmol/l was used based on 
calcium absorption studies [244]. 
 52 
4.3.3 GDM (II) 
According to national recommendations, the diagnosis of GDM was based on 
a two-hour 75 g oral glucose tolerance test (OGTT) [243]. GDM was diagnosed 
if the OGTT results exceeded cut-offs for one or more values: fasting plasma 
glucose ≥ 5.3 mmol/l, 1-h ≥ 10.0 mmol/l and 2-h ≥ 8.6 mmol/l. OGTT was 
performed on 490/723 (54.5%) of the participating mothers at gestational 
weeks 10–40 between October 2012 and March 2014. These data were 
collected from prenatal and medical records.  
4.3.4 DIETARY DATA (I AND III) 
Data on maternal diet during the last month of pregnancy were collected 
retrospectively using a 22-item semi-quantitative FFQ. Mothers filled in the 
frequency of food group usage with a given standard portion size. The 
frequency of food groups consumed was recorded from 0 = not used to 8 = 
four to six times a day or more.  
Infant food consumption and vitamin D intake at 1 year of age were 
collected between January 2014 and June 2015 with a 3-day food record 
administered to parents or daycare personnel who had received written 
instructions on how to accurately fill it out (III). At the 1-year follow-up, 
families were instructed to record all of the infant’s foods, drinks and 
supplements with their amounts, as well as breastfeeding frequencies during 
the food record period. The volume of breast milk ingested was not recorded. 
Only 2% (16/739) were at daycare at the time of the food record.  
Food records and nutrient intakes were processed with AivoDiet software 
(version 2.0.2.3, Aivo Oy, Turku, Finland), which utilizes Fineli (version 
Fine68, 2016), the National Food Composition Database maintained by the 
National Institute for Health and Welfare. Five infants had a 2-day, and the 
rest (n=734) had a 3-day food record. Categorizing the food items into more 
general food groups was based on the FinDiet survey [245] with some 
modifications. Composite food items from the food record were unable to be 
further broken down into individual food items. Thus, for example, the “meat 
dishes” food group includes all ingredients used in the dish, such as meat, 
cream, potatoes, and carrots.  
The infant’s breastfeeding status at 1 year of age was based on the food 
records in Study III. In Study IV, breastfeeding duration was obtained from 
repeated questionnaires within study diaries.  
4.3.5 INFANT ANTHROPOMETRICS (II–IV) 
Birth size, including birth weight (kg), length (cm), and head circumference 
(cm), was measured by midwives according to standard procedure. These data 
and the duration of the pregnancy were retrospectively collected from birth 
records. Birth size and postnatal growth parameters were transformed into 
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standard deviation scores (SDSs) using Finnish sex- and age-specific 
normative data for fetal [246] and postnatal growth [247]. The Ponderal index 
was calculated (birth weight (kg) / birth length (m)3) and standardized into a 
sex-specific z-score within the study subjects. 
Infant postnatal growth was measured at 6-month and 1-year follow-up 
visits by a pediatrician or research nurse. Head circumference was measured 
with an inelastic tape and recorded to the nearest 0.5 cm (Seca®, Hamburg, 
Germany). Length (cm) was measured with a tabletop meter in a supine 
position, and weight (kg) was measured with a scale (Seca®, Hamburg, 
Germany). Normal weight, length, length-adjusted weight, and head 
circumference were determined between -2.0 and +2.0 SDS. 
4.3.6 STATISTICS 
The normality of the variables was visually inspected. Descriptive subject 
characteristics were reported as means, medians, standard deviations, or 
percentages and were tested with independent sample t-tests, Mann-Whitney 
U-tests, ANOVA, Pearson’s chi-squared and Fisher’s exact tests. Outliers of 
UCB and pregnancy 25(OH)D were omitted in Studies I and II to obtain 
reliable results. Outliers were identified with a Normal probability plot of 
residuals, Leverage and Cook’s Distance diagnostic tests. ANOVA and 
ANCOVA with Bonferroni post hoc tests were used when applicable. 
Univariate and multivariate linear regression models were employed. A 
change of 25(OH)D during pregnancy [Δ25(OH)D] was calculated as UCB 
25(OH)D – early pregnancy 25(OH)D (I). 
Covariates were chosen based on their significant associations with the 
outcome or independent variable and literature. Some missing information of 
covariates was imputed in Study II using median or mean values in subgroups 
by GDM status. In Study IV, missing values of covariates were multiple 
imputed (5 imputations). In Study IV, infant 25(OH)D concentration was used 
as a proxy for the infant’s total vitamin D intake. 
Seasons were defined as follows: winter from December to February; 
spring from March to May; summer from June to August; and fall from 
September to November. Seasons as a covariate were coded using dummy 
variables (with fall as a reference) in linear regression models. 
Maternal DPs were created based on food group frequencies in the FFQ 
using principal component analysis (PCA) (I). Standardized PCA scores were 
calculated for each mother. These scores ranked pregnant women according 
to their adherence to the specific DP. 
An elaboration model [248] was applied to study the tracking of 25(OH)D 
from early pregnancy to UCB by conducting a series of regression models in 
Study I. We examined changes in the beta coefficient of pregnancy 25(OH)D 
in regression models; a decline in beta coefficients meant that the added factor 
promoted the tracking of 25(OH)D from pregnancy to UCB, and an increase 
prevented it. A multivariate linear regression model was used to determine the 
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most important predictors for declining and increasing 25(OH)D during 
pregnancy in subgroups of Declined (Δ25(OH)D < 0 nmol/l) and Increased 
(Δ25(OH)D > 0 nmol/l) 25(OH)D during pregnancy. 
The difference in 25(OH)D between GDM and non-GDM mothers was 
investigated with ANCOVA adjusted for season, maternal age, education, and 
prepregnancy BMI (II). Birth size was examined by 25(OH)D categories of <50 
nmol/l, 50–74.9 nmol/l, 75–125 nmol/l and >125 nmol/l with ANCOVA  
adjusted for maternal education, prepregnancy BMI, maternal prepregnancy 
smoking, gestational diabetes mellitus, parity, maternal height, maternal 
GWG, and UCB/pregnancy 25(OH)D as changing covariates. 
Infant postnatal size was investigated in linear regression models and in 
25(OH)D categories of <50 nmol/l, 50–74.9 nmol/l (reference group), 75–125 
nmol/l and >125 nmol/l with ANCOVA adjusted for corresponding birth size 
SDS, maternal and paternal height z-scores, and infant 25(OH)D at 1 year 
when applicable (II and IV). Statistical significance between only the reference 
group of 50–74.9 nmol/l and other groups were tested with linear regression. 
In linear regression models, three models were used: Model 1, unadjusted; 
Model 2, adjusted for corresponding birth size SDS, maternal and paternal 
height z-scores, and infant 25(OH)D (except in analyses of infant 25(OH)D); 
and Model 3, adjusted for Model 2 covariates and for maternal and paternal 
prepregnancy BMI, parental smoking status, parental education level, family 
income level, and duration of breastfeeding. 
A change in infant growth (length, weight, length-adjusted weight, and 
head circumference) between birth, 6 months, and 1 year of age was calculated 
by saving the residuals from linear regression models of body size SDS at each 
successive age versus the corresponding body size SDS at all earlier ages. These 
residuals were referred to as “conditional growth.” Conditional growth reflects 
growth rates between growth periods. Univariate and multivariate linear 
regression analyses were used to explore associations between 25(OH)D and 
infant conditional growth with similar adjustments as described above. 
Associations were considered significant at P < 0.05. All statistical analyses 
were conducted using the IBM SPSS program for Windows version 22 (IBM, 
Chicago, IL, USA). 
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5 RESULTS 
5.1 SUBJECT CHARACTERISTICS (I–IV) 
The characteristics of the parents and infants are reported in Tables 12 and 13. 
Mothers and fathers averaged 32 and 34 years old, respectively (Table 12). Of 
the participating mothers, 76% were highly educated (I). The majority of the 
mothers (72%, I) and almost half of the fathers (47%, IV) had a normal BMI. 
Of the mothers, 95% took vitamin D supplements during pregnancy, with a 
mean intake of 16 μg/day (I). In pregnant women, daily supplemental intake 
of vitamin D ranged from zero to 197.5 μg, with the majority consuming 10 μg 
(Table 11). Of the mothers, 15% smoked before pregnancy (II) (Table 12). For 
63% of the mothers, the infant was their firstborn. 
Infants were born with birth weights appropriate for gestational age 
according to the VIDI study protocol. Infant size parameters were measured 
at three time points; at birth, 6 months, and 1 year of age (Table 13). Almost 
all infants had a normal body size at all time points. Half the infants were girls, 
and 79% and 40% were breastfed at the age of 6 months and 1 year, 
respectively (IV) (Table 12). 
 
Table 11 Maternal supplemental intake of vitamin D in Study I (n=584) 
Supplemental vitamin D intake, μg/day Proportion of women, % 
<10 15 
10 54 
10.1–19.9 6 
20 9 
>20 16 
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Table 12 Subject characteristics in Studies I–IV 
 
Study I Study II Study III Study IV 
N 584 723 739 798 
Maternal 
 
Age, years 31.6 (4.2) 32.1 (4.4) 31.6 (4.2) 31.7 (4.3) 
Prepregnancy BMI, kg/m2 23.3 (3.8) 24.6 (4.2) - 23.2 (3.6) 
     Missing, n 
 
3 
 
4 
Supplemental vitamin D 
intake, μg/day 
15.7 (16.9) 14.5 (13.7) - - 
     Missing, n 
 
26 
  
Education, higher2, % 76 75 76 75 
     Missing, n 
 
12 1 10 
Nullipara, % 63 63 - 63 
     Missing, n 
   
2 
Smoking, yes1, % 14 15 15 16 
     Missing, n 
 
22 
 
5 
Paternal 
    
Age, year3 - - 34.1 (5.3) 33.6 (5.3) 
     Missing, n 
  
7 39 
Prepregnancy BMI, kg/m2 - - - 25.7 (3.4) 
     Missing, n 
   
27 
Education, higher3, % - - 61 62 
     Missing, n 
  
10 20 
Smoking, yes1, % - - 24 26 
     Missing, n 
  
7 14 
Family income level 
    
     <40,000 €/year, % - - 17 19 
     40,000–89,000 €/year, % - - 62 60 
     >90,000 €/year, % - - 21 21 
     Missing, n 
  
73 109 
Infant     
Sex, girls, % 52 51 49 51 
Breastfed at 1 year4, %   36 40 
Duration of breastfeeding, 
months 
- - - 10.7 (5.6) 
     Missing, n    13 
Values are mean (SD) unless stated otherwise. A dash indicates no data available or not applied in 
the study. All values are unimputed. 
BMI, body mass index. 
1 In Studies I–II, smoking status refers to prepregnancy smoking, and in Studies III–IV, smoking refers 
to combined smoking status at prepregnancy and at infant age of 2 years. 
2 At least a bachelor level education. 
3 Refers to age when infant was 1 year old. 
4 In Study III, breastfeeding status was obtained from food records, and in Study IV from study diaries. 
  
 57 
 
Table 13 Infant size at three time points 
  
At birth 
n=723 
At 6 months 
n=798 
At 1 year 
n=798 
Gestational age, week 40.2 (1.1) - - 
Age, months - 6.0 (0.2) 12.0 (0.4) 
Length, cm 50.4 (1.7) 67.5 (2.2) 75.3 (2.5) 
Length, SDS -0.19 (0.88) -0.47 (0.97) -0.54 (1.01) 
Weight, kg 3.5 (0.4) 8.0 (0.9) 9.8 (1.1) 
Weight, SDS -0.25 (0.80) 0.21 (1.07) -0.24 (1.01) 
Length-adjusted weight, SDS - 0.15 (1.11) 0.02 (1.02) 
Head circumference1, cm 35.3 (1.4) 43.6 (1.2) 46.5 (1.2) 
Head circumference1, SDS -0.10 (0.96) -0.30 (0.94) -0.42 (0.94) 
Mid-upper-arm circumference2, cm - - 15.3 (1.2) 
Normal length SDS (-2.0–2.0), % 98 94 93 
Normal weight SDS (-2.0–2.0), % 100 94 96 
Normal length-adjusted weight 
SDS (-2.0–2.0), % - 94 96 
Normal head circumference SDS 
(-2.0–2.0), %1 96 96 96 
Values are means (SD) unless stated otherwise; a dash indicates no data available. 
SDS, standard deviation score, which is based on Finnish sex- and age-specific normative data for fetal and infant 
growth. 
1 At birth, 2 values are missing; at 6 months, 21 values are missing; and at 1 year, 5 values are missing. 
2 39 values are missing. 
 
 
5.2 25(OH)D CONCENTRATION (I, II, IV) 
Table 14 demonstrates the mean 25(OH)D concentrations at three time points: 
in early pregnancy, at birth, and in infancy at 1 year of age. Pregnancy samples 
were collected on average at gestational week 11. Almost all pregnant women, 
newborns, and infants were vitamin D sufficient (25(OH)D ≥50 nmol/l) (96–
99%). In Study I, pregnancy and UCB 25(OH)D values applied were 
uncorrected (see section 4.3.2). Thus, the prevalence figure of maternal 
vitamin D sufficiency in Study I differs from Studies II and IV (99% in Study I 
vs. 96% in Studies II and IV). Figure 3 presents prevalence values of vitamin 
D status in categories of <50 nmol/l, 50–74.9 nmol/l, 75–125 nmol/l and >125 
nmol/l (IV). The majority of subjects had 25(OH)D concentration between 75 
and 125 nmol/l (Figure 3). 
Pregnancy and UCB 25(OH)D correlated positively, although the 
correlation was modest (r=0.27; P<0.001). Further, pregnancy and infant 
25(OH)D had no correlation (r=0.07; P=0.081), but UCB and infant 25(OH)D 
at 1 year of age had a weak positive correlation (r=0.15; P<0.001). 
 
  
 58 
 
Table 14 Mean 25-hydroxyvitamin D concentration [25(OH)D] in pregnancy, in umbilical cord 
blood (UCB) and in infancy at the age of 1 year 
 
Study I Study II Study IV 
N 584 723 798 1  
Mean (SD) 
Pregnancy 25(OH)D, nmol/l 
[uncorrected, reported in Study I]2 
81.5 (19.1) 
[88.8 (19.0)] 
81.7 (19.7) 82.4 (20.3) 
Gestational age at sampling, week 11.0 (1.0) 11.3 (1.9) 11.3 (2.2) 
UCB 25(OH)D, nmol/l 
[uncorrected, reported in Study I]2 
80.9 (22.3) 
[88.3 (22.0)] 
79.9 (19.9) 82.5 (25.8) 
Infant 25(OH)D at 1 year, nmol/l - - 98.9 (29.0) 
A dash indicates no data available for the study. 
1 Number of participants for pregnancy values was 671, for UCB values 780. 
2 The uncorrected 25(OH)D value was reported in Study I, as these were not yet corrected for the 
methodological changes in the IDS-iSYS system (see section 4.3.2). 
 
 
 
 
 
 
Figure 3 25-hydroxyvitamin D concentration [25(OH)D] in categories of <50, 50–74.9, 75–125, 
and >125 nmol/l in pregnancy (n=671), umbilical cord blood (UCB) (n=780), and in infancy at 
the age of 1 year (n=798) (IV). 
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5.3 DETERMINANTS OF MATERNAL AND NEWBORN 
25(OH)D CONCENTRATIONS (I) 
5.3.1 SEASON 
Seasonal differences in 25(OH)D occurred but were relatively modest (Figure 
4). In pregnancy and at birth, the 25(OH)D concentration was highest in 
summer, but in infancy, it was highest in winter. 
5.3.2 MATERNAL DIET 
The role of maternal diet was investigated as dietary patterns (DP) derived 
from FFQ data with PCA. Five DPs were chosen as the most interpretable, 
explaining 46% of the variation in maternal diet. The first was named “goodies 
and snacks,” and it was characterized by frequent consumption of 
sweets/candy/lollipops, pudding/chocolate/ice cream, sweet and salty 
pastries, snacks and squash/soft drink. The second DP was named “health-
conscious” and was characterized by foods such as fresh and cooked vegetables 
(including potato), fruits/berries (including fruit or berry juice), fish, and 
seeds/beans. The third DP, “meat,” included meat, chicken, or egg foods, cold 
cuts from sausages, sausages, and ready-made marinated meat or fish 
products. The fourth DP, named “sandwich and dairy,” was characterized by 
frequent consumption of rye bread/other whole-grain bread/muesli, cheese, 
margarine, and fluid dairy/vegetable milk products. The fifth DP included 
mild and strong alcoholic drinks and was named “alcohol.” Standardized DP 
scores were calculated for each of the mothers and for each DP. This means 
that all the mothers had a score for goodies and snacks DP, health-conscious 
DP and meat DP, sandwich and dairy DP and alcohol DP. 
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Figure 4 Mean (SEM) values of 25-hydroxyvitamin D at different seasons in pregnancy 
(n=584, ANOVA P=0.036), in umbilical cord blood (UCB) (n=584, ANOVA P=0.001) (I) and in 
infancy at 1 year of age (n=798, ANOVA P=0.001; IV). 
 
5.3.3 TRACKING OF 25(OH)D DURING PREGNANCY 
To establish the most important modifiers for maternal and newborn 
25(OH)D concentrations, we investigated which maternal and other 
underlying factors influenced the relationship between early pregnancy 
25(OH)D and UCB 25(OH)D, i.e., the tracking of 25(OH)D during pregnancy 
(Figure 5, Table 15). This was achieved by multiple linear regressions, in which 
we examined how the standardized beta coefficient of pregnancy 25(OH)D 
changed (as UCB 25(OH)D was the dependent) when adding other factors into 
the regression model (Figure 5), besides identifying significant associations 
between the factors and UCB 25(OH)D (Table 15). A decline in beta coefficient 
indicated that the factor promoted the tracking of 25(OH)D from pregnancy 
to UCB, and an increase in beta coefficient indicated that the factor prevented 
it. Factors are grouped by their similar characteristics (Figure 5). 
High maternal physical activity, education level, supplemental vitamin D 
intake, and number of daily supplements promoted the tracking of 25(OH)D 
during pregnancy (Figure 5), but multiparity prevented it. Maternal 25(OH)D 
was also dependent on the season, of which the strongest modifier was 
summer season at delivery promoting 25(OH)D during pregnancy. Other 
relevant factors that had no effect on the tracking of 25(OH)D but associated 
with UCB 25(OH)D were maternal smoking and the “sandwich and dairy” DP 
during pregnancy (Table 15). All these factors were chosen for further analysis. 
  
  
   
 
  
Figure 5. Modifiers affecting the 
tracking of 25-hydroxyvitamin D 
[25(OH)D] from early pregnancy 
to umbilical cord blood in a 
crude model after adding factors 
separately and together. A 
decline in B coefficient reflects a 
promoting effect of the factor, 
and an increase reflects the 
prevention of tracking the 
25(OH)D during pregnancy. 
Reprinted and modified with 
permission from Springer 
Nature: European Journal of 
Nutrition, Hauta-alus et al. 2018 
(Study I). 
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Table 15 Factors associating with UCB 25(OH)D 
 β B 95% CI P 
Pregnancy 25(OH)D, nmol/l 0.28 0.32 0.23, 0.41 <0.001 
Maternal lifestyle factors     
Prepregnancy physical activity, min/day 0.11 0.13 0.04, 0.22 0.005 
Prepregnancy smoking, number of 
cigarettes/day -0.10 -0.57 -1.02, -0.12 0.014 
Postpregnancy smoking, number of 
cigarettes/day -0.08 -1.26 -2.51, -0.01 0.049 
Prepregnancy alcohol use, portion/week 0.03 0.36 -0.49, 1.21 0.411 
Maternal background factors     
Education, higher vs. lower 0.08 4.17 0.15, 8.19 0.042 
Prepregnancy BMI, kg/m2 0.03 0.15 -0.30, 0.61 0.510 
Age, year 0.04 0.20 -0.21, 0.60 0.346 
Parity -0.15 -6.62 -10.16, -3.08 <0.001 
Nutritional factors     
Goodies and snacks DP score 0.02 0.49 -1.24, 2.21 0.579 
Health conscious DP score 0.07 1.63 -0.09, 3.36 0.064 
Meat DP score -0.05 -1.02 -2.75, 0.70 0.244 
Sandwich and dairy DP score 0.09 1.97 0.25, 3.69 0.025 
Alcohol DP score 0.02 0.52 -1.20, 2.25 0.551 
Supplemental vitamin D intake, μg/day 0.17 0.23 0.12, 0.33 <0.001 
Number of supplements 0.18 2.99 1.72, 4.25 <0.001 
Season and duration of gestation   
Spring at pregnancy sampling 0.03 1.96 -3.02, 6.95 0.439 
Summer at pregnancy sampling -0.05 -2.20 -6.10, 1.69 0.266 
Winter at pregnancy sampling 0.10 5.18 0.97, 9.39 0.016 
Spring at delivery -0.12 -5.45 -8.89, -2.01 0.002 
Summer at delivery 0.16 8.77 4.59, 12.96 <0.001 
Winter at delivery 0.02 1.35 -3.14, 5.85 0.555 
Pregnancy sampling, gestational week -0.13 -0.40 -0.64, -0.16 0.001 
Duration of gestation, days 0.07 0.19 -0.03, 0.41 0.096 
Values are standardized β, and unstandardized B coefficients with 95% confidence intervals (95% CI) conducted 
with standard linear regression; the modifier and pregnancy 25(OH)D are independent variables and UCB 
25(OH)D is dependent. P values <0.05 are in bold.  
25(OH)D, 25-hydroxyvitamin D concentration; BMI, body mass index; DP, dietary pattern 
 
5.3.4 PREDICTORS FOR DECLINING AND INCREASING 25(OH)D 
CONCENTRATION DURING PREGNANCY 
After identifying the factors modifying the tracking of 25(OH)D (Figure 5 
and Table 15), the most relevant factors were investigated further in two 
groups: Declined (Δ25(OH)D < 0 nmol/l) and Increased (Δ25(OH)D > 0 
nmol/l) 25(OH)D during pregnancy (Table 15). This enabled us to identify the 
key predictors for 25(OH)D in pregnancy. These relevant factors were selected 
based on results in the tracking analyses besides issues of collinearity and 
simplicity. 
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Maternal supplemental vitamin D intake was a positive predictor of UCB 
25(OH)D in both groups (Table 16). Furthermore, in the Declined 25(OH)D 
group, physical activity and higher education were positive predictors. In the 
Increased group, sandwich and dairy DP characterized by frequent 
consumption of vitamin D–fortified foods and summer season were positive 
predictors, but multiparity was a negative predictor of UCB 25(OH)D (Table 
16). A subanalysis was further conducted among pregnant women with a 
clinically relevant decline in 25(OH)D concentration during pregnancy 
(Δ25(OH)D ≤ -10.0; n=209). Factors associating with an extensive decline in 
25(OH)D were prepregnancy smoking (B= -0.45; 95% CI: -0.83, -0.07; P= 
0.021) and multiparity (B= -2.79; 95% CI: -5.39, -0.18; P= 0.036). 
 
 
  
 Table 16 Predictors of UCB 25(OH)D in groups with Declined and Increased 25(OH)D during pregnancy 
 
 
 
 
 
 
 
 
 
 
Values are unstandardized B coefficients with 95% confidence intervals (95% CI) conducted with standard multivariate linear regression; all determinants are used 
simultaneously as independent variables and UCB 25(OH)D as dependent. P values <0.05 are in bold. 
25(OH)D, 25-hydroxyvitamin D; UCB, umbilical cord blood; Declined group, Δ25(OH)D <0.00 nmol/l; Increased group, Δ25(OH)D >0.00 nmol/l; DP, dietary pattern. 
  
 Declined (n=321) Increased (n=263) 
 B 95% CI P B 95% CI P 
Prepregnancy smoking, number of cigarettes/day -0.24 -0.57, 0.09 0.152 -0.54 -1.13, 0.06 0.075 
Prepregnancy physical activity, min/day 0.07 0.00, 0.13 0.041 0.05 -0.06, 0.16 0.397 
Pregnancy 25(OH)D, nmol/l 0.49 0.42, 0.55 <0.001 0.86 0.73, 1.00 <0.001 
Supplemental vitamin D intake, μg/day 0.07 0.00, 0.14 0.037 0.17 0.02, 0.32 0.031 
Sandwich and dairy DP, score  0.27 -0.85, 1.39 0.633 3.07 0.77, 5.38 0.009 
Summer season at delivery, yes vs. no 2.58 -0.53, 5.69 0.104 8.81 3.81, 13.81 0.001 
Parity, multi- vs. nulliparous -1.51 -3.85, 0.83 0.204 -6.11 -10.93, -1.29 0.013 
Education, higher vs. lower 4.32 1.42, 7.22 0.004 -4.96 -10.35, 0.43 0.071 
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5.4 ASSOCIATION BETWEEN MATERNAL 25(OH)D AND 
GDM (II) 
Of the mothers, 11% (81/723) were diagnosed with GDM. Mean pregnancy and 
UCB 25(OH)D concentrations were similar in GDM and non-GDM mothers, 
adjusted for season, age, education, and prepregnancy BMI (Table 17, Figure 
6). OGTT was performed on 55% (490/723) of the mothers. Results remained 
unchanged after including only those mothers with performed OGTT (data not 
shown). Further, there was no association between pregnancy 25(OH)D and 
fasting plasma glucose, 1-h glucose, or 2-h glucose (P for all >0.53) or between 
UCB 25(OH)D and glucose values (P for all >0.25) (data not shown). 
The prevalence of vitamin D deficiency [25(OH)D <50 nmol/l] in 
pregnancy was 4.9% (4/81) in GDM and 3.3% (21/642) in non-GDM mothers 
(P = 0.51). However, at delivery in UCB, more GDM mothers were vitamin D 
deficient compared with non-GDM mothers [7.4% (6/81) vs. 2.8% (18/642) (P 
= 0.042)]. Of the 6 deficient GDM mothers, 5 (83%) were smokers, whereas in 
non-GDM mothers, 4 out of 18 were smokers (24%) (P = 0.018). 
 
Table 17 Mean pregnancy and UCB 25(OH)D in 81 GDM and 639 non-GDM mothers 
 Unadjusted model Adjusted model 
 Mean 95% CI P Mean 95% CI P 
 Pregnancy 25(OH)D, nmol/l 
GDM 80.0 75.7, 84.3 0.403 81.7 77.3, 86.2 0.998 
Non-GDM 82.0 80.4, 83.5  81.7 80.2, 83.3  
 UCB 25(OH)D, nmol/l 
GDM 78.4 74.0, 82.7 0.444 79.1 74.7, 83.5 0.692 
Non-GDM 80.2 78.6, 81.7  80.1 78.5, 81.6  
Values are mean and 95% confidence interval (95% CI) conducted with ANCOVA. 
Adjustments are for season, maternal age, education, and prepregnancy BMI. 
GDM, gestational diabetes mellitus; 25(OH)D, 25-hydroxyvitamin D; UCB, umbilical cord blood. 
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Figure 6 Scatter plot of GDM (n=81) and non-GDM 
(n=639) mothers’ pregnancy and UCB 25(OH)D 
concentrations. The line represents an unadjusted 
mean value. GDM, gestational diabetes mellitus; 
25(OH)D, 25-hydroxyvitamin D; UCB, umbilical 
cord blood. 
 
5.5 INFANT VITAMIN D INTAKE AND FOOD SOURCES 
(III) 
Mean (SD) daily vitamin D intake from food (excluding breast milk) was 7.5 
μg (3.2) in non-breastfed (n=476), and 3.8 μg (3.0) in partially breastfed 
infants (n=263) at the age of 1 year. The range of vitamin D intake from food 
was 0–30.7 μg/day. The main food sources of vitamin D were infant formula, 
dairy milk, porridge, and fish dishes (Table 18). The vitamin D in porridges 
originated from vitamin D–fortified mass-produced porridges and porridges 
containing vitamin D–fortified milk. For non-breastfed infants, over half the 
vitamin D came from dairy, especially infant formula, and for breastfed 
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infants, the food sources of vitamin D were more varied, including dairy milk 
and fish foods (Table 18).  
 
 
Table 18 Food sources of vitamin D in non-breastfed (n=476) and breastfed (n=263) 1-year-old 
infants 
Foods Non-breastfed Breastfed 
 Mean daily intake, μg 
Proportion 
of daily 
intake, % 
Mean daily 
intake, μg 
Proportion 
of daily 
intake, % 
Dairy and plant-based milk 
products 4.8 64 1.3 35 
Infant formula 2.3 31 0.4 11 
Skim milk 1.3 17 0.3 7 
Low-fat milk (1.5%) 0.9 12 0.3 7 
Plant-based milk products 0.1 2 0.1 3 
Porridges 1.5 19 1.0 25 
Mass-produced baby food 
porridge 1.0 13 0.6 17 
Milk-based porridge 0.5 6 0.3 8 
Fish dishes 0.6 8 0.9 24 
Dietary fats 0.3 3 0.3 7 
Meat dishes 0.2 3 0.2 5 
Other 0.1 2 0.1 5 
Total1 7.5 99 3.8 101 
1 Percentages do not add up to 100% due to rounding. 
 
5.6 INFLUENCE OF 25(OH)D CONCENTRATION IN 
PREGNANCY AND INFANCY ON INFANT GROWTH 
(II AND IV) 
5.6.1 PREGNANCY AND UCB 25(OH)D AND PRENATAL GROWTH (II) 
Birth size was investigated in categories of 25(OH)D of <50 nmol/l, 50–74.9 
nmol/l, 75–125 nmol/l, and >125 nmol/l (Figure 7) (Hauta-alus et al. 
unpublished results). Pregnancy 25(OH)D had no association with fetal 
growth (P for all ≥0.073) (Figure 7). However, newborns with UCB 25(OH)D 
75–125 nmol/l had smaller head circumference compared with newborns of 
50–74.9 nmol/l (P=0.015) (Figure 7). Further examination revealed a linear 
negative association between UCB 25(OH)D and head circumference (B -1.74; 
95% CI -3.25, −0.23; P = 0.024). This association remained after adjusting for 
maternal education, prepregnancy BMI, maternal prepregnancy smoking, 
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GDM, parity, maternal height, maternal GWG and pregnancy 25(OH)D, and 
mode of delivery (vaginal, vacuum-assisted, or cesarean section).  
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Figure 7 Association of pregnancy (A) and umbilical cord blood (UCB) (B) 25-hydroxyvitamin D 
concentration [25(OH)D] with birth size adjusted for maternal education, prepregnancy body 
mass index, maternal prepregnancy smoking, gestational diabetes, parity, maternal height, 
maternal gestational weight gain, and UCB/pregnancy 25(OH)D as changing covariates. 
25(OH)D concentration is expressed in categories of <50 nmol/l, 50–74.9 nmol/l, 75–125 nmol/l 
and >125 nmol/l. Values are adjusted means with 95% confidence intervals. * indicates a 
statistically significant association by ANCOVA (P <0.05). Number of subjects in pregnancy 
25(OH)D categories: <50, n=22; 50–74.9, n=237; 75–125, n=400 (398 in head circumference 
analysis); >125, n=15. Number of subjects in UCB 25(OH)D categories: <50, n=22; 50–74.9, 
n=269 (267 in head circumference analysis); 75–125, n=369; >125, n=14. SDS, standard 
deviation score, based on Finnish sex- and gestational age-specific data for fetal growth. The 
ponderal index is in z-scores.  
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5.6.2 PREGNANCY AND UCB 25(OH)D AND POSTNATAL GROWTH 
(IV) 
Pregnancy 25(OH)D had no linear association with infant growth at 6 months 
or 1 year of age (Table 19). However, when dividing pregnancy 25(OH)D into 
categories, it was discovered that mothers whose pregnancy 25(OH)D was 
above 125 nmol/l had the shortest (in length) (P=0.048), lightest (in weight) 
(P=0.016), and thinnest (in length-adjusted weight) (P=0.013) infants at 6 
months of age compared with the 50–74.9 nmol/l reference group (Figure 8). 
Further, at 1 year of age, infants of mothers of above 125 nmol/l during 
pregnancy were the thinnest compared with the reference group (P=0.021) 
(Figure 9). 
UCB 25(OH)D had a negative linear association with length at 6 months 
(Table 19). Infants with UCB 25(OH)D above 125 nmol/l were the shortest 
(P=0.011), and infants with UCB 25(OH)D below 50 nmol/l were the thinnest 
at 6 months compared with the reference group (P=0.034) (Figure 8). The 
negative linear association between UCB 25(OH)D and head circumference in 
birth remained until 6 months and 1 year of age but attenuated after 
adjustments (Tables 19 and 20). The growth rate of infants with higher UCB 
25(OH)D was slower between birth and 6 months but was accelerated between 
6 months and 1 year (Table 21 and 22). 
 
 
  
 Table 19 Associations between 25(OH)D concentrations and infant postnatal growth at 6 months of age 
 
 
 
 
 
 
 
 
 
Values are B coefficients (95% CI) per 10 nmol/L higher in 25(OH)D concentration based on linear regression. 
* Statistically significant linear association, P <0.05. 
SDS, standard deviation score, based on Finnish sex- and age-specific normative data for infant growth; 25(OH)D, blood 25-hydroxyvitamin D concentration; 
UCB, umbilical cord blood. 
1 Model 2 is adjusted for corresponding birth size SDS, maternal and paternal height z-scores, and Infant 25(OH)D which served as a marker of infant 
supplemental vitamin D intake. 
2 Model 3 is adjusted for model 2 covariates and in addition to maternal and paternal prepregnancy BMI, smoking status of the parents, parental education, 
family income level, and duration of breastfeeding. 
3 The number of subjects varies in analyses due to missing values of head circumferences; for pregnancy 25(OH)D in Model 1: n=650, in Models 2 and 3: 
n=649; for UCB 25(OH)D in Model 1: n=759, in Models 2 and 3: n=757. 
 
  
 SDS 
Pregnancy 25(OH)D, 10 nmol/L, 
n=671 Length Weight 
Length-adjusted 
weight Head circumference
3 
   Model 1, unadjusted -0.02 (-0.06, 0.01) -0.03 (-0.07, 0.01) -0.03 (-0.07, 0.01) -0.02 (-0.05, 0.02) 
   Model 2, adjusted1 -0.02 (-0.05, 0.01) -0.03 (-0.07, 0.00) -0.03 (-0.07, 0.01) -0.02 (-0.05, 0.01) 
   Model 3, adjusted2 -0.02 (-0.05, 0.01) -0.03 (-0.06, 0.01) -0.03 (-0.07, 0.02) -0.02 (-0.05, 0.01) 
UCB 25(OH)D, 10 nmol/L, 
n=780     
   Model 1, unadjusted -0.04 (-0.06, -0.01)* -0.01 (-0.04, 0.02) 0.00 (-0.03, 0.03) -0.03 (-0.06, -0.01)* 
   Model 2, adjusted1 -0.03 (-0.05, -0.01)* 0.00 (-0.01, 0.02) 0.01 (-0.02, 0.04) -0.02 (-0.03, 0.00) 
   Model 3, adjusted2 -0.03 (-0.05, -0.01)* 0.00 (-0.02, 0.03) 0.01 (-0.02, 0.04) -0.02 (-0.04, 0.01) 
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 Table 20 Associations between pregnancy and UCB 25(OH)D concentrations and infant growth at 1 year of age 
 
 
 
 
 
 
 
 
 
 
 
 
Values are B coefficients (95% CI) per 10 nmol/L higher in 25(OH)D concentration based on linear regression. 
* Statistically significant linear association, P <0.05. 
SDS, standard deviation score, based on Finnish sex- and age-specific normative data for infant growth; 25(OH)D, blood 25-hydroxyvitamin D concentration; UCB, 
umbilical cord blood. 
1 Model 2 is adjusted for corresponding birth size SDS, maternal and paternal height z-scores, and Infant 25(OH)D, which served as a marker of infant supplemental 
vitamin D intake. 
2 Model 3 is adjusted for model 2 covariates and in addition to maternal and paternal prepregnancy BMI, smoking status of the parents, parental education, family income 
level, and duration of breastfeeding. 
3 Number of subjects varies in analyses due to missing values of head circumferences; for Pregnancy 25(OH)D in Model 1: n=666, in Models 2 and 3: n=665; for UCB 
25(OH)D in Model 1: n=775, in Models 2 and 3: n=773. 
 
 
  
 SDS 
Pregnancy 25(OH)D, 10 
nmol/L, n=671 Length Weight Length-adjusted weight Head circumference
3 
   Model 1, unadjusted -0.01 (-0.05, 0.03) -0.02 (-0.06, 0.01) -0.03 (-0.07, 0.01) -0.02 (-0.05, 0.02) 
   Model 2, adjusted1 -0.01 (-0.05, 0.02) -0.03 (-0.06, 0.01) -0.03 (-0.07, 0.01) -0.02 (-0.05, 0.02) 
   Model 3, adjusted2 -0.01 (-0.04, 0.02) -0.02 (-0.06, 0.01) -0.02 (-0.06, 0.02) -0.02 (-0.05, 0.02) 
UCB 25(OH)D, 10 nmol/L, 
n=780     
   Model 1, unadjusted -0.01 (-0.03, 0.02) -0.01 (-0.04, 0.01) -0.02 (-0.04, 0.01) -0.03 (-0.05, 0.00)* 
   Model 2, adjusted1 0.00 (-0.03, 0.02) 0.00 (-0.02, 0.01) -0.01 (-0.04, 0.02) -0.01 (-0.02, 0.00) 
   Model 3, adjusted2 0.00 (-0.03, 0.02) -0.01 (-0.03, 0.02) -0.01 (-0.04, 0.02) -0.01 (-0.04, 0.01) 
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Figure 8 Association of (A) pregnancy and (B) umbilical cord blood (UCB) 25-hydroxyvitamin 
D concentration [25(OH)D] with infant growth parameters at 6 months of age. 25(OH)D 
concentration is expressed in categories of <50 nmol/l, 50–74.9 nmol/l (reference group), 
75–125 nmol/l and >125 nmol/l. Values are adjusted means with 95% confidence intervals. 
Analyses are adjusted for corresponding birth size standard deviation score (SDS), maternal 
and paternal height z-scores, and infant 25(OH)D, which served as a marker of infant 
supplemental vitamin D intake. * indicates a statistically significant association (P <0.05), and 
is only shown between the reference group and other groups. Number of subjects in 
pregnancy 25(OH)D categories: <50, n=25; 50–74.9, n=218; 75–125, n=412; >125, n=16, 
and in UCB 25(OH)D categories: <50, n=29; 50–74.9, n=294; 75–125, n=425; >125, n=32. 
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Figure 9 Association of (A) pregnancy and (B) cord blood (UCB) 25-hydroxyvitamin D 
concentration [25(OH)D] with infant growth parameters at 1 year of age. 25(OH)D 
concentration is expressed in categories of <50 nmol/l, 50–74.9 nmol/l (reference group), 75–
125 nmol/l and >125 nmol/l. Values are adjusted means with 95% confidence intervals. 
Analyses are adjusted for corresponding birth size standard deviation score (SDS), maternal 
and paternal height z-scores, and infant 25(OH)D, which served as a marker of infant 
supplemental vitamin D intake. * indicates a statistically significant association (P <0.05) and is 
only shown between the reference group and other groups. Number of subjects in pregnancy 
25(OH)D categories: <50, n=25; 50–74.9, n=218; 75–125, n=412; >125, n=16, and in UCB 
25(OH)D categories: <50, n=29; 50–74.9, n=294; 75–125, n=425; >125, n=32. 
  
 Table 21 Associations between 25(OH)D and infant conditional growth at 6 months of age 
 
 
 
 
 
 
 
 
 
 
Values are B coefficients (95% CI) per 10 nmol/L higher in 25(OH)D concentration based on linear regression. 
* Statistically significant linear association, P < 0.05. 
25(OH)D, 25-hydroxyvitamin D concentration; UCB, umbilical cord blood. 
1 Model 2 is adjusted for maternal and paternal height z-scores, and infant 25(OH)D, which served as a marker of infant supplemental vitamin D intake. 
2 Model 3 is adjusted for model 2 covariates and in addition to maternal and paternal prepregnancy BMI, smoking status of the parents, parental 
education, family income level, and duration of breastfeeding. 
3 Number of subjects varies in analyses due to missing values of head circumferences; for Pregnancy 25(OH)D in Models 1, 2, and 3: n=649; for UCB 
25(OH)D in Models 1, 2, and 3: n=757. 
 
 
  
 Conditional growth at 6 months 
Pregnancy 25(OH)D, 10 
nmol/L, n=671 
Length Weight Length-adjusted 
weight 
Head circumference3 
   Model 1, unadjusted -0.02 (-0.06, 0.01) -0.04 (-0.07, 0.00) -0.03 (-0.07, 0.00) -0.02 (-0.06, 0.02) 
   Model 2, adjusted1 -0.03 (-0.06, 0.01) -0.03 (-0.07, 0.00) -0.03 (-0.07, 0.01) -0.02 (-0.06, 0.01) 
   Model 3, adjusted2 -0.02 (-0.06, 0.01) -0.03 (-0.06, 0.01) -0.02 (-0.06, 0.02) -0.03 (-0.07, 0.01) 
UCB 25(OH)D, 10 nmol/L, 
n=780 
    
   Model 1, unadjusted -0.03 (-0.06, -0.01)* 0.00 (-0.03, 0.03) 0.01 (-0.02, 0.03) -0.02 (-0.04, 0.01) 
   Model 2, adjusted1 -0.03 (-0.06, -0.01)* 0.00 (-0.01, 0.02) 0.01 (-0.02, 0.04) -0.02 (-0.03, 0.00) 
   Model 3, adjusted2 -0.03 (-0.06, -0.01)* 0.00 (-0.02, 0.03) 0.01 (-0.02, 0.04) -0.02 (-0.05, 0.01) 
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 Table 22 Associations between 25(OH)D and infant conditional growth at 1 year of age 
 
 
 
 
 
 
 
 
 
 
Values are B coefficients (95% CI) per 10 nmol/L higher in 25(OH)D concentration based on linear regression. 
* Statistically significant association, P < 0.05. 
25(OH)D, 25-hydroxyvitamin D concentration; UCB, umbilical cord blood. 
1 Model 2 is adjusted for maternal and paternal height z-scores and infant 25(OH)D, which served as a marker of infant supplemental vitamin D intake 
(except when infant 25(OH)D was used as a dependent). 
2 Model 3 is adjusted for model 2 covariates and in addition to maternal and paternal prepregnancy BMI, smoking status of the parents, parental education, 
family income level, and duration of breastfeeding. 
3 Number of subjects varies in analyses due to missing values of head circumference; for Pregnancy 25(OH)D in Models 1, 2, and 3: n=644; for UCB 
25(OH)D in Models 1, 2, and 3: n=752; for infant 25(OH)D in Models 1, 2, and 3: n=770. 
 
 
 Conditional growth at 1 year 
Pregnancy 25(OH)D, 10 nmol/L, 
n=671 
Length Weight Length-adjusted 
weight 
Head 
circumference3 
   Model 1, unadjusted 0.02 (-0.02, 0.05) -0.01 (-0.05, 0.03) -0.01 (-0.05, 0.02) 0.00 (-0.04, 0.04) 
   Model 2, adjusted1 0.01 (-0.03, 0.05) -0.01 (-0.04, 0.03) -0.01 (-0.05, 0.03) 0.00 (-0.04, 0.04) 
   Model 3, adjusted2 0.01 (-0.02, 0.05) 0.00 (-0.04, 0.04) 0.00 (-0.04, 0.03) 0.00 (-0.04, 0.04) 
UCB 25(OH)D, 10 nmol/L, n=780  
   Model 1, unadjusted 0.04 (0.01, 0.07)* -0.01 (-0.04, 0.02) -0.03 (-0.05, 0.00) 0.00 (-0.03, 0.03) 
   Model 2, adjusted1 0.04 (0.01, 0.07)* -0.01 (-0.02, 0.01) -0.02 (-0.04, -0.01) 0.00 (-0.01, 0.02) 
   Model 3, adjusted2 0.04 (0.01, 0.07)* -0.01 (-0.04, 0.02) -0.03 (-0.05, 0.00) 0.00 (-0.03, 0.03) 
Infant 25(OH)D, 10 nmol/L, n=798  
   Model 1, unadjusted 0.00 (-0.03, 0.02) -0.02 (-0.04, 0.01) -0.02 (-0.05, 0.00) -0.02 (-0.05, 0.00) 
   Model 2, adjusted1 0.00 (-0.03, 0.02) -0.02 (-0.04, 0.01) -0.02 (-0.05, 0.00) -0.02 (-0.05, 0.00) 
   Model 3, adjusted2 0.00 (-0.03, 0.02) -0.02 (-0.04, 0.01) -0.02 (-0.05, 0.00) -0.02 (-0.05, 0.00) 
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5.6.3 INFANT 25(OH)D AND GROWTH (IV) 
Infant 25(OH)D at 1 year of age associated negatively with length, weight, 
length-adjusted weight, and head circumference at 1 year, although the 
association with length and head circumference attenuated after adjustments 
(Table 23). Further, infants above 125 nmol/l were the lightest (P=0.022) and 
thinnest compared with the 50–74.9 nmol/l reference group (P=0.032) 
(Figure 10). Table 24 summarizes the findings between maternal and infant 
vitamin D status and infant growth. 
 
Table 23 Associations between infant 25(OH)D concentration and growth at 1 year of age 
 
Values are B coefficients (95% CI) per 10 nmol/l higher in 25(OH)D concentration based on linear regression. 
* Statistically significant linear association, P <0.05. 
SDS, standard deviation score, based on Finnish sex- and age-specific normative data for infant growth; 25(OH)D, 
blood 25-hydroxyvitamin D concentration; UCB, umbilical cord blood. 
1 Model 2 is adjusted for the corresponding birth size SDS, maternal and paternal height z-scores, and infant 
25(OH)D, which was served as a marker of infant supplemental vitamin D intake (except when infant 25(OH)D 
was used as a dependent). 
2 Model 3 is adjusted for model 2 covariates and in addition to maternal and paternal prepregnancy BMI, smoking 
status of the parents, parental education, family income level, and duration of breastfeeding until 1 year of age. 
3 Number of subjects varies in analyses due to missing values of head circumferences in Model 1: n=793, in 
Models 2 and 3: n=791. 
 
 
  
 SDS 
Infant 25(OH)D, 10 
nmol/l, n=798 Length Weight 
Length-
adjusted weight 
Head 
circumference3 
Model 1, 
unadjusted 
-0.03 
(-0.05, 0.00)* 
-0.03 
(-0.06, -0.01)* 
-0.02 
(-0.05, 0.00)* 
-0.02 
(-0.05, 0.00)* 
Model 2, adjusted1 -0.02 
(-0.04, 0.00) 
-0.03 
(-0.05, -0.01)* 
-0.03 
(-0.05, 0.00)* 
-0.02 
(-0.04, 0.01) 
Model 3, adjusted2 -0.02 
(-0.04, 0.00) 
-0.03 
(-0.05, -0.01)* 
-0.03 
(-0.05, 0.00)* 
-0.02 
(-0.04, 0.01) 
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Figure 10 A cross-sectional association between infant 25-hydroxyvitamin D concentration 
[25(OH)D] and infant growth parameters at 1 year of age. 25(OH)D concentration is expressed in 
categories of <50 nmol/L, 50–74.9 nmol/L (reference group), 75–125 nmol/L and >125 nmol/L. 
Values are adjusted means with 95% confidence intervals and are adjusted for corresponding 
birth size standard deviation score (SDS), maternal and paternal height z-scores. * indicates a 
statistically significant association (P <0.05) and is only shown between the reference group and 
other groups. Number of subjects in infant 25(OH)D categories: <50, n=10; 50–74.9, n=160; 75–
125, n=493; >125, n=135. 
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Table 24 Summary of the negative (-) and positive (+) associations between 
25(OH)D and infant growth. Details about the association are shown in 
parentheses as linear (L) and non-linear (N-L); Only significant associations are in 
unadjusted analysis; non-significant associations are shown as “NS” (II and IV) 
Infant growth 
Pregnancy 
25(OH)D UCB 25(OH)D 
Infant 25(OH)D 
at 1 year 
At birth    
Length NS NS  
Weight NS NS  
Length-adjusted weight NS NS  
Head circumference NS - (L, N-L)  
At 6 months of age 
   
Length - (N-L) - (L, N-L)  
Weight - (N-L) NS  
Length-adjusted weight - (N-L) + (N-L)  
Head circumference NS - (L unadjusted)  
At 1 year of age 
   
Length NS NS - (L unadjusted) 
Weight NS NS - (L, N-L) 
Length-adjusted weight - (N-L) NS - (L, N-L) 
Head circumference NS - (L unadjusted) - (L unadjusted) 
25(OH)D, 25-hydroxyvitamin D concentration; UCB, umbilical cord blood. 
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6 DISCUSSION 
6.1 SUMMARY OF THE MAIN FINDINGS 
This study explored current vitamin D status in pregnant women and their 
newborns and whether it associates with GDM, infant birth size, and postnatal 
growth in full-term infants with normal birth weight. In addition, we examined 
whether infant vitamin D status associates with growth at 1 year of age in 
infants participating in a vitamin D intervention trial. The main findings can 
be summarized as follows: 
Our data indicated that, overall, the pregnant women and their newborns 
were vitamin D sufficient as the concentration of 25(OH)D in almost all of the 
participating subjects was ≥50 nmol/l. Moreover, 99% of 1-year-old infants 
were vitamin D sufficient. 
Of pregnant women, 95% used vitamin D supplements with a mean daily 
intake of 16 μg. Seasonal variations of 25(OH)D were moderate, with values 
being highest in summer both during pregnancy and at birth. Besides vitamin 
D supplementation, other positive predictors of 25(OH)D during pregnancy 
were dietary pattern (DP) characterized by regular use of vitamin D–fortified 
foods and prepregnancy physical activity. In contrast, factors associating with 
declining 25(OH)D in pregnancy were prepregnancy smoking and multiparity. 
GDM was observed in 11% of the pregnant women. Pregnancy and UCB 
25(OH)D concentrations did not differ between GDM and non-GDM women. 
Furthermore, 25(OH)D did not associate with OGTT results. 
The mean daily intake of vitamin D from food was 7.5 μg in non-breastfed 
and 3.8 μg in breastfed 1-year-old infants. The main food sources of vitamin D 
were infant formula, dairy milk, porridge, and fish foods. 
Higher maternal and infant 25(OH)D were associated with slower infant 
growth. Mothers with high pregnancy 25(OH)D (>125 nmol/l) had the 
shortest (in length), lightest (in weight) and thinnest (in length-adjusted 
weight) infants at 6 months of age. Higher UCB 25(OH)D associated with 
smaller head circumference at birth and slower linear growth at 6 months of 
age, whereas infants with UCB 25(OH)D <50 nmol/l were thinnest at 6 
months. In infants, higher UCB 25(OH)D associated with slower linear growth 
from birth to 6 months but with accelerated growth from 6 months to 1 year of 
age. Infants with 25(OH)D >125 nmol/l were lightest and thinnest at 1 year of 
age.   
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6.2 INTERPRETATION OF THE RESULTS 
6.2.1 VITAMIN D STATUS (I, IV) 
The majority (96%) of the pregnant women and their newborns and infants at 
1 year of age (99%) were vitamin D sufficient, defined as 25(OH)D ≥50 nmol/l. 
Infants in this study were allocated to daily vitamin D supplementation doses 
of 10 μg and 30 μg. It appears that maternal and newborn 25(OH)D 
concentrations have increased compared with previous reports from Finland. 
In line with studies in adults [24, 25], elderly [26], and older children [153, 
249, 250], vitamin D status has improved in Finland. The majority of pregnant 
women (61%), newborns (55%), and 1-year-old infants (62%) had 25(OH)D 
between 75 and 125 nmol/l. Values above 125 nmol/l in pregnancy, UCB, and 
infancy, which are considered a possible threshold for adverse effects by IOM 
(presently NAM) [114], were observed as 2%, 4%, and 17%, respectively. In the 
VIDI study, 32% of the infants receiving 30 μg vitamin D had 25(OH)D >125 
nmol/l at 1 year and 39% at 2 years of age [242], without evidence for vitamin 
D toxicity [242, 251].  
Some researchers consider that higher maternal vitamin D status (>100 
nmol/l) than is generally considered sufficient (≥50 nmol/l) should be 
achieved to prevent maternal and neonatal health risks [23, 252]. Further, 
they highlight the need for maternal vitamin D intake of at least 100 μg/day. 
A similar discussion has been ongoing regarding non-pregnant adults [1, 21, 
253]. Based on the findings of this thesis, such views on vitamin D appear 
extravagant. 
The exceptionally high maternal 25(OH)D levels in Finnish pregnant 
women can be explained by the high adherence to vitamin D supplementation 
and the national vitamin D food fortification policy. Vitamin D food 
fortification in fluid dairy products and dietary fats was doubled in 2010. 
Likewise, in 2011, vitamin D supplementation guidelines were revised in 
pregnant women to year-round supplementation (10 μg) instead of only 
winter-time supplementation.  
Finland is an exceptional example of successful public health policy 
regarding vitamin D [64, 96]. Parallel to observations in countries with similar 
strategies, vitamin D intake has increased, and vitamin D deficiency has 
declined [127, 128, 131, 167, 254]. However, still in 2011, 9% of Finnish women 
had a serum 25(OH)D concentration of <50 nmol/l [24], but this was a great 
improvement from 2000, when 57% of women had 25(OH)D <50 nmol/l [24]. 
Although it was not examined in this thesis, pregnant immigrant women may 
be at increased risk of vitamin D deficiency [254, 255]. Our results suggest that 
vitamin D status is generally sufficient among Finnish pregnant women, at 
least in women of Northern European ethnicity. 
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6.2.2 DETERMINANTS OF MATERNAL 25(OH)D (I) 
The key determinants of maternal 25(OH)D were season, education, 
supplemental vitamin D intake, DP characterized by frequent consumption of 
vitamin D–fortified dairy products and margarine, physical activity, smoking 
before pregnancy, and parity. As expected, maternal 25(OH)D was highest in 
summer. Supplemental vitamin D intake and DP with frequent consumption 
of vitamin D–fortified foods were positive predictors of 25(OH)D during 
pregnancy. On average, a daily dose of supplemental vitamin D was 16 μg, 
ranging from zero to 198 μg. Our findings indicate that the proportion of 
pregnant women taking vitamin D supplements has increased from 40% in 
1998–99 to current 95% [132], which is in accordance with other recent 
reports [137, 139]. 
In pregnant women, the mean intake of supplemental vitamin D was higher 
than recommended. Based on data acquired in 2008–2011, the median intake 
of supplemental vitamin D was 6 μg among pregnant women [139]. Our 
findings are parallel to the FinDiet 2012 survey, which reported that vitamin 
D intake from supplements was 16 μg/day in non-pregnant women (excluding 
the elderly). In that survey, the total intake of vitamin D was 25 μg/day, with 
55% of women using vitamin D supplements [245]. Based on the most recent 
FinDiet survey in 2017, vitamin D intake and the proportion of supplement 
users has continued to rise [92]. Currently in Finland, the average daily total 
intake of vitamin D is 10 μg in women (13 μg in men). However, in those 
women who consumed vitamin D supplements, the mean vitamin D intake 
was 36 μg/day, while in those not taking supplements, it was 9 μg/day. 
Comparing FinDiet 2017 to the 2012 survey is limited due to different 
methodologies and statistical modeling in vitamin D intake [92]. 
The contribution of vitamin D food fortification to maternal vitamin D 
status was clearly indicated in this thesis, although we could not measure the 
absolute total dietary intake of vitamin D. The “sandwich and dairy” DP 
included frequent consumption of vitamin D–fortified dairy and margarine 
and correlated with maternal 25(OH)D. This is logical, as the main food 
sources of vitamin D in Finnish adults, besides fish, have been described as 
dietary fats and dairy milk [92, 245]. Moreover, consumption of these foods 
has been linked to 25(OH)D in previous Finnish studies [24, 161, 162]. 
Prepregnancy physical activity promoted the tracking of 25(OH)D during 
pregnancy, which is parallel to few other studies [166, 256]. The effect of 
physical activity may be a result of more outdoor activities, i.e., more UVB 
exposure, or it may be explained by BMI, as physical activity most likely 
reduces BMI, and lower BMI associates with higher 25(OH)D. However, 
contrary to many studies [166-168, 256], prepregnancy BMI was not 
associated with UCB 25(OH)D in this study. This may be because the majority 
of women had normal BMI (72%). Nevertheless, physical activity might 
indicate an overall healthy lifestyle, which has been linked to vitamin D status.  
Determinants for a decline in 25(OH)D during pregnancy were 
prepregnancy smoking and multiparity. A similar trend has been observed in 
 83 
other studies on pregnant women [166, 169, 170, 216]. Multiparity has been 
detected to correlate with lack of supplement use [171]. Hence, the effect of 
multiparity on maternal 25(OH)D might reflect changed family 
circumstances, as personal resources are limited and vitamin D 
supplementation neglected. In general, and based on the results of this study, 
health promotion in dark-skinned, smoking, and multiparous pregnant 
women should be emphasized in prenatal clinics to ensure sufficient vitamin 
D status in all pregnant women. 
6.2.3 MATERNAL 25(OH)D AND GDM (II) 
GDM was observed in 11% of the pregnant women, which was in accordance 
with national statistics. Vitamin D status in pregnancy or in UCB did not differ 
between GDM and non-GDM women. Furthermore, 25(OH)D concentrations 
had no linear association with OGTT results. The proportion of women with 
UCB 25(OH)D <50 nmol/l was higher in GDM (7.4%) than in non-GDM 
women (2.8%). However, almost all GDM women with 25(OH)D below 50 
nmol/l were smokers prior to pregnancy. This may imply that vitamin D status 
presented as a general health indicator. In addition, it has been speculated that 
smoking and vitamin D deficiency may have synergistic effects on the risk of 
GDM [257]. Because our cohort included a very low number of subjects with 
25(OH)D <50 nmol/l, we could not reliably examine this. 
There is evidence that vitamin D status is inferior in pregnant women with 
GDM compared to non-GDM women [195] and that vitamin D 
supplementation decreases the risk of GDM [125], but the full picture remains 
uncertain due to the low quality of RCTs [125, 258]. Furthermore, the high 
heterogeneity of studies included in the meta-analyses limits the conclusions. 
The challenge in examining the relationship between vitamin D and GDM is 
in their common determinants, such as obesity, smoking, ethnicity, and other 
socioeconomic and lifestyle factors, which often confound the results. Indeed, 
Lu et al. estimated that low maternal vitamin D status associated with 
increased GDM risk only in analyses without adjustments for confounders 
[192]. It may be that in populations with overall sufficient vitamin D status, as 
in our cohort, maternal 25(OH)D has no relation to GDM. 
6.2.4 INFANT VITAMIN D INTAKE FROM FOOD AND FOOD SOURCES 
(III) 
Vitamin D intake from food averaged 7.5 and 3.8 μg/day in non-breastfed and 
breastfed 1-year-old infants, respectively, thus not reaching the recommended 
intake of 10 μg. This emphasizes the need for vitamin D supplementation to 
achieve the recommended intake. Nevertheless, vitamin D intake from food 
has increased markedly in infants from the latest estimation of 4–5 μg/day in 
1999–2004, prior to the doubling of the vitamin D food fortification [150, 151]. 
Recently, a parallel increase in vitamin D intake in older children has been 
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observed. Total vitamin D intake from supplements and food has averaged 6–
7 μg/day in the early 2000s among children 3–4 years old [151], but recently 
(2015–2016), vitamin D intake from only food was 8.8 μg/day in the same age 
group [259]. Since infants in this study received vitamin D supplements, the 
total vitamin D intake was probably adequate. Formerly, the average total 
vitamin D intake has been adequate among 1-year-olds [151, 154]. 
In the USA, a country with vitamin D food fortification, comparable daily 
mean intake of 7.o μg of vitamin D from food has been calculated among 
infants aged 6–11 months [260]. In a comparison, in Italy, which has no 
vitamin D fortification guidelines, infants 6–12 months old have a mean daily 
vitamin D intake of 4.0 μg [261]. 
In line with earlier findings [150, 152], we observed that the main vitamin 
D food sources were infant formula, dairy milk, porridge, and fish foods. The 
porridges that contained vitamin D were either vitamin D–fortified mass-
produced porridges or porridges cooked in vitamin D–fortified milk. The main 
dietary sources varied somewhat between non-breastfed and breastfed 
infants. In non-breastfed infants, infant formula and dairy milk were the 
predominant contributors of vitamin D intake, and in breastfed infants, they 
were dairy milk and fish foods. 
6.2.5 VITAMIN D AND INFANT GROWTH (II, IV) 
In contrast to our expectations, maternal vitamin D status associated inversely 
with pre- and postnatal growth in infants. This is a novel finding. The reason 
this is emerging not until now may be because only recently there have been 
populations with high 25(OH)D, especially in environments with minimal 
UVB exposure. 
Previous evidence suggests a relationship between maternal vitamin D 
deficiency (<30 nmol/l) and low birth weight [213]. Our results were based on 
vitamin D–sufficient subjects. Moreover, infants in this study were healthy 
and full-term with normal birth weight. In this thesis, no linear relation or 
association with the applied 25(OH)D cut-offs 50, 75 and 125 nmol/l existed 
between maternal 25(OH)D and birth weight. However, in the original 
publication of Study II, we observed that mothers with pregnancy 25(OH)D 
>80 nmol/l had heavier newborns compared to those with <80 nmol/l. An 
additional analysis in this thesis showed a tendency that newborns of mothers 
with pregnancy 25(OH)D above 125 nmol/l had the lowest mean birth weight, 
although not statistically significant. Some experts reckons that the positive 
effects of maternal vitamin D on offspring growth are due to general 
improvement in nutritional or health status [69], but this relationship may be 
more complex. 
In this study, at birth, higher UCB 25(OH)D associated with smaller head 
circumference. This association remained until 1 year of age but attenuated 
after adjustments with birth head circumference. Inconsistent evidence exists 
for the relationship between maternal vitamin D status and head 
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circumference at birth. A meta-analysis by Tous et al. concluded that vitamin 
D deficiency (<30 nmol/l) associated with smaller head circumference at birth 
but low 25(OH)D defined as <50 or <75 nmol/l did not [213]. Yet some studies, 
including ours, have observed an inverse linear association between maternal 
vitamin D status and head circumference at birth [230, 262]. In those studies, 
the mean or median maternal 25(OH)D has been relatively high (71–74 
nmol/l) compared with other studies. Bi et al. concluded in their meta-analysis 
based on 11 RCTs that maternal vitamin D supplementation had no effect on 
birth head circumference [209]. 
In this thesis, infants born to mothers with pregnancy 25(OH)D above 125 
nmol/l were the shortest (in length), lightest (in weight), and thinnest (in 
length-adjusted weight) at 6 months of age, and thinnest also at 1 year of age. 
In addition, an inverse relationship existed between UCB 25(OH)D and linear 
growth at 6 months, but not at 1 year of age. This may be explained by a slower 
growth between birth and 6 months and a catch-up growth between 6 months 
and 1 year. Infants with UCB 25(OH)D <50 nmol/l at birth were the thinnest 
at 6 months of age. 
Only a few studies have examined maternal vitamin D status and postnatal 
growth in infancy, and they show inconsistent results. This may be partly due 
to low data quality, varying thresholds for vitamin D deficiency, and residual 
confounding. Furthermore, subjects in previous studies have had quite a low 
vitamin D status. In Gambian and Singaporean studies with relatively high 
maternal 25(OH)D, maternal vitamin D status had no relation to postnatal 
growth parameters [223, 224] or had an inverse association with length at 6 
months [230]. Even though Bi et al. concluded that maternal vitamin D 
supplementation increased several growth parameters during infancy [209], 
Roth et al. did not detect any effect of vitamin D supplementation on postnatal 
growth in a large RCT [218]. Severe vitamin D deficiency (<30 nmol/l) may 
possibly impair fetal and infant growth, but if this cut-off is exceeded, no 
benefits are observed with higher 25(OH)D concentrations [213, 224, 263]. 
One further possible explanation for the inconsistent results between 
vitamin D and growth may be catch-up or accelerated growth in lower birth-
weight infants of vitamin D–deficient mothers. This can lead to inverse [225, 
264] or nonexistent associations between maternal 25(OH)D and offspring 
growth in later infancy [168]. Our results may indicate a similar catch-up 
growth, not in infants born to vitamin D–deficient mothers, but to mothers 
with high vitamin D status. Rapid growth or pronounced adiposity accrual in 
childhood can increase the risk for later obesity [228, 265-267]. Regarding 
later childhood growth, maternal 25(OH)D had no effect on linear growth at 9 
years [214], but lower maternal 25(OH)D associated with greater fat mass at 6 
years of age [264]. The newborn’s own 25(OH)D concentration had no effect 
on overweight in 7-year-old children [268]. 
As with maternal vitamin D status, the infant’s own 25(OH)D 
concentration also associated inversely with infant growth in this study. This 
was seen in all growth parameters in unadjusted analyses, while only 
 86 
associations for weight and length-adjusted weight were confirmed after 
adjustments for birth size and parental heights. Infants with 25(OH)D >125 
nmol/l were the lightest and thinnest at 1 year of age. In the VIDI cohort, on 
average, growth parameters did not differ between the supplementation 
groups of 10 μg and 30 μg [242]. Thus, our results might imply an individual 
response to vitamin D supplementation on 25(OH)D concentrations [269]. 
The few previous reports on infant vitamin D and growth have been 
conflicting. In line with our results, vitamin D status correlated negatively with 
length and BMI among Danish 9-month-old infants [237].  
Altogether, our findings may suggest an inverse U-shaped association 
between vitamin D status and infant growth, as has been suggested by a few 
previous studies [270-273]. Moreover, higher vitamin D status or intake have 
been associated with other impaired health outcomes in children [220, 274, 
275] as well as in adults [72, 276-278]. Within the VIDI cohort, we have 
reported that higher UCB 25(OH)D associated with higher inflammation 
markers at birth and increased allergic sensitization at 1 year of age [279, 280]. 
Studies involving subjects with high 25(OH)D (>100 nmol/l) have been scarce 
[281], and therefore, data on the effects of high vitamin D status on health 
outcomes is limited. 
Multiple factors influence infant growth patterns, including nutrition and 
hormonal regulation. Linear growth is largely long bone growth localized to 
the growth plate. It has been suggested that sufficient 25(OH)D would increase 
bone mineral density and, hence, lead to enhanced growth, but the evidence is 
constricted [18]. The mechanisms by which vitamin D could affect childhood 
growth beyond maintaining normal bone mineralization (i.e., preventing 
rickets) are unclear. Though not yet clearly understood, 1,25(OH)2D probably 
has several regulatory functions in bone remodelling in the growth plate [282]. 
High vitamin D status and the mechanism for how it could impair growth 
may also be related to the normal mineral homeostasis regulated by vitamin 
D. The central function of vitamin D is to maintain normal circulating calcium 
at the expense of bone, if needed. High 1,25(OH)2D levels have been linked to 
factors inhibiting bone mineralization and enhancing bone resorption through 
stimulation of osteoclasts [283], thus possibly affecting growth. However, it is 
not known whether elevated 25(OH)D also leads to a significant increase in 
1,25(OH)2D. 
Another possible pathway through which vitamin D can act on infant 
growth is the growth hormone IGF-1 axis, which is essential for normal 
growth. In vitamin D–deficient children, vitamin D supplementation has 
resulted in a significant increase in IGF-1 concentrations [284, 285]. 
Furthermore, IGF-1 may stimulate renal production of 1,25(OH)2D [286]. It 
has been speculated that high 25(OH)D stunts infant growth by inhibiting the 
function of IGF-1 [273]. The pathways mediating the effects of vitamin D on 
growth and the clinical relevance of our findings remain to be explored in 
future studies.  
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6.3 STRENGTHS AND LIMITATIONS 
The main strength of this large VIDI study is in the data, which were collected 
in a standardized manner from a single maternity hospital. All mothers were 
of Northern European ethnicity, which resulted in a relatively homogenous 
group of subjects that can be perceived both as a strength and a limitation. A 
multi-center study would have probably resulted in a larger variation in 
subject characteristics in terms of socioeconomic status. In general, mothers 
were highly educated, were of normal weight, and a majority of them gave 
birth to their first child. In addition, families were mainly from Helsinki or the 
surrounding capital area. Thus, the results of this thesis may not be 
generalized to all pregnant women and infants in Finland. The strength of this 
thesis is in its in-depth analysis between vitamin D and health outcomes with 
relevant adjustments for possible confounders. A further strength is that this 
study covered all seasons. 
One limitation in this study was that we did not have information on the 
absolute vitamin D intake during pregnancy or infancy. We applied circulating 
25(OH)D concentration as an indicator of total vitamin D intake from diet and 
skin synthesis. Several confounding variables were extracted from self-
administered questionnaires, but these were checked by study nurses. Not all 
women underwent OGTT according to national guidelines. This may have 
underestimated the true prevalence of GDM. However, subgroup analyses of 
women with performed OGTT confirmed our results. 
The volume of breast milk was unknown; however, its contribution to 
infant vitamin D intake is estimated to be minimal. We could not calculate the 
absolute contribution of specific food items on vitamin D intake because 
limitations in the applied software programme, i.e., composite foods, could not 
be dismantled. Further, we were unable to calculate an estimation of the usual 
dietary intake of vitamin D, taking into account the day-to-day variability of 
food consumption [287, 288]. Yet, we calculated the mean value of the 3-day 
food record rather than proportions of infants with below or above the 
recommended intake diminishing the possible bias. 
Another restraint was maternal 25(OH)D values, which were corrected to 
achieve better comparability between plasma and serum samples and because 
of changes in the IDS-iSYS method by the manufacturer. This method had a 
slight tendency to overestimate the 25(OH)D values, though it did not affect 
the associations between 25(OH)D and health outcomes. We did not take part 
in the VDSP; thus, comparing the prevalence of vitamin D deficiency with 
other studies, populations, and decades should be done with caution. A limited 
number of subjects on both extreme ends of vitamin D status may have 
constrained our analysis. This study can be regarded as longitudinal because 
we had data from early pregnancy until the offspring was 1 year old, albeit 
cross-sectional characteristics prevail in many analyses. Thus, causal 
relationships cannot be determined. 
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7 CONCLUSIONS AND FUTURE 
PERSPECTIVES 
Vitamin D status was sufficient among pregnant women and newborns in this 
study. Likewise, infants at the age of 1 year who participated in a vitamin D 
supplementation trial had sufficient vitamin D status. Key maternal factors 
that increased 25(OH)D during pregnancy were dietary intake of vitamin D by 
both supplementation and diet and physical activity. Determinants associating 
with declining maternal vitamin D status were smoking and multiparity. 
Maternal vitamin D status had no relation to GDM. Daily mean dietary intake 
of vitamin D from food was 7.5 μg in non-breastfed and 3.8 μg in breastfed 1-
year-old infants, indicating that vitamin D supplementation is required to 
achieve the recommendation of 10 μg. 
Higher maternal and infant 25(OH)D associated with slower infant growth. 
These results may indicate a possible inverse U-shaped relationship between 
vitamin D status and growth. Thus, there is no need to aim for higher maternal 
or infant 25(OH)D concentrations with excessive supplementation, as this 
may be disadvantageous for infant growth.  
The clinical relevance and long-term effects of these findings are to be 
explored in future studies. Regarding the VIDI cohort, the first step is to repeat 
these analyses in 2-year-old infants. In addition, it would be of interest to 
examine the effect of the infant’s total and supplemental intake of vitamin D 
on growth. The long-term effects are to be investigated in the VIDI follow-up 
study starting in 2019-2020 when the children are 6 to 7 years of age. 
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